

QSAR Studies on Thiazolidines: A Biologically Privileged Scaffold

YENAMANDRA S. PRABHAKAR*, V. RAJA SOLOMON, MANISH K. GUPTA, S.B.
KATTI*

*Medicinal and Process Chemistry Division, Central Drug Research Institute,
Lucknow – 226 001, India*

E-mail: (YSP) yenpra@yahoo.com

(SBK) setu_katti@yahoo.com

Tel.: +91 522 2612411

Fax: +91 522 2624305

A large number of drugs and biologically relevant molecules contain heterocyclic systems. Often the presence of hetero atoms or groupings imparts preferential specificities in their biological responses. Amongst the heterocyclic systems, thiazolidine is a biologically important scaffold known to be associated with several biological activities. Some of the prominent biological responses attributed to this skeleton are antiviral, antibacterial, antifungal, antihistaminic, hypoglycemic, anti-inflammatory activities. This diversity in the biological response profiles of thiazolidine has attracted the attention of many researchers to explore this skeleton to its multiple potential against several activities. Many of these synthetic and biological explorations have been subsequently analyzed in detailed quantitative structure-activity relationship (QSAR) studies to correlate the respective structural features and physicochemical properties with the activities to identify the important structural components in deciding their activity behavior. In this, drugs or any biologically active molecules may be viewed as structural frames consisting of strategically positioned functional groups that will interact effectively with the complementary groups/sites of the receptor. With this in focus, the present article reviews the QSAR studies of diverse biological activities of the thiazolidines published during the past decade.

Keywords: Thiazolidines, QSAR, molecular modeling

1. Introduction
2. Chemistry
 - 2.1 Thiazolidine
 - 2.2 Thiazolidine-4-carboxylic acids
 - 2.3 Properties of thiazolidine-4-carboxylic acids
 - 2.4 Thiazolidin-4-ones
 - 2.5 Properties of thiazolidine-4-ones
- 3 QSAR and Modeling studies
 - 3.1 QSAR and Modeling studies
 - 3.1.1 Cyclooxygenase Inhibitors
 - 3.1.2 Nitric oxide synthase inhibitors
 - 3.1.3 Adenosine receptor antagonists
 - 3.1.4 Histamine (H₁) antagonists
 - 3.1.5 H⁺K⁺-ATPase Inhibitors
 - 3.1.6 Antiepileptic agents
 - 3.2 Metabolic disorders
 - 3.2.1 β₃-receptor agonists
 - 3.2.2 Neuropeptide Y5 Receptor Antagonists
 - 3.2.3 PPAR Agonists
 - 3.2.4 Aldose Reductase Inhibitors
 - 3.2.5 Thromboxane A2 receptor antagonists
 - 3.3 Anti-infective Agents
 - 3.3.1 Anti-HIV Agents
 - 3.3.2 Antifungals Agents
 - 3.3.3 Octopamine Agonists
 - 3.3.4 Trehalase Inhibitors
- 4 Conclusion
- 5 References

List of abbreviations:

AF	<i>Aspergillus fumigatus</i>
AIDS	acquired immune deficiency syndrome
ANN	artificial neural network
AR	aldose reductase
ATPase	adenosin tri-phosphatase
BPN	back propagation neural networks

CA	<i>Candida albicans</i>
cAMP	cyclic-adenosine mono phospahte
CN	<i>Cryptococcus neoformans</i>
CODESSA	comprehensive descriptors for structural and statistical analysis
CoMFA	comparative molecular field analysis
CoMSIA	comparative molecular similarity analysis
COX	cyclooxygenase
CPE	carrageenan mice paw edema
CP-MLR	combinatorial protocol in multiple linear regression
E/L	enzyme ligand interaction
FA	factor analysis
G/PLS	genetic partial least squares
GAGs	glycosaminoglycans
GFA	genetic function approximation
HBTU	2-(1H-Benzotrizo-1-yl)-1,1,3,3-tetramethyluraniumhexafluorophospate
HIV	human immunodeficiency virus
MEDV	molecular electronegativity distance vector
MFA	molecular field analysis
MLR	multiple linear regression
MMPs	metalloproteinases
MOE	molecular operiting environment
MOPAC	molecular orbital partial atomic charge
MSA	molecular shape analysis
NNRTIs	non-nucleoside reverse transcriptase inhibitors
NO	nitric oxide
NPY5R	neuropeptide Y5 receptor
NRTIs	nucleoside reverse transcriptase inhibitors
NSAIDs	Non-steroidal anti-inflammatory drugs
OA	octopamine Agonists
PCR	principle components regression
PLS	partial least square
PPARs	peroxisome proliferator-activated receptors
QSAR	quantitative structure-activity relationship
RSM	receptor surface model

RT	reverse rranscriptase
TM	<i>Tricophyton mentagrophyte</i>
TXA2	Thromboxane A2
TZDs	thiazolidinediones
VSMP	variable selection and modeling method based on prediction

1.0

Introduction

Quantitative structure activity relationship (QSAR) study envisages establishment of mathematical / functional relationship between the chosen activity and selected properties of the congeneric series of compounds. In the early years of QSAR, most of the explorations revolved around the numerical expressions and presentation of the correlations and/ or patterns from regression, discriminant and clustering approaches. With the advancements in the computer hardware performance and software, the graphical expression and visual presentation of modeling results have taken long-strides along with the mathematical / functional relationships. These strategies have been effectively put to use particularly in the area of rational drug design. This is evident from a large number of original research publications and review articles published in the literature [1-3]. In this backdrop the present article highlights the QSAR and molecular modeling explorations carried out on thiazolidine heterocyclic systems. In chemical parlance the term thiazolidine refers to five membered ring system containing sulfur and nitrogen; the numbering system is as shown in Fig 1.

Figure 1

In small molecule heterocyclic compounds, thiazolidine is a recognised scaffold for potential drugs and drug candidates. Anticonvulsant, sedative, antidepressant, anti-inflammatory, antihypertensive, antihistaminic and antiarthritic activities are a few among many other biological responses shown by this scaffold (Table 1) [4].

Table 1

Further more, the avenues of simple chemical transformations in the generation of diverse variety of pendants on thiazolidine scaffold has fascinated the medicinal

chemists to explore the wealth of biological information underneath it. Therefore a conscious effort is made in the chemistry part of the present review to cull out select modifications of the thiazolidine skeleton namely thiazolidine-4-carboxylic acids and 4-thiazolidinones from the vast array of thiazolidines.

2.0

Chemistry

2.1

Thiazolidine

The parent compound thiazolidine can be obtained in high yield as hydrochloride by the reaction of cysteamine hydrochloride with aqueous formaldehyde at ambient temperature (Scheme 1)[5].

Scheme 1

By logical extension of the scheme one can generate substituted thiazolidine and its homologs by the reaction of appropriate carbonyl compounds with the suitable α -aminothiols (Scheme 2) [6].

Scheme 2

Furthermore, many thiazolidines are in equilibrium with its acyclic thiol form alternately in aqueous media, with the β -mercaptoalkylamine and the carbonyl compound from which they were formed. The position of the equilibrium depends on the nature of the ring substituents (Scheme 2) [7]. Thiazolidines with unsubstituted ring nitrogen (N3) are readily hydrolyzed by boiling in aqueous acidic or basic solution and the hydrolysis is completed in the presence of a compound which reacts with either of the cleavage products. The presence of

substituents on the nitrogen atom (N3) stabilizes the thiazolidine ring. Under strong acidic or basic conditions or at high temperature, 1, 3-thiazolidines undergo epimerization followed by decomposition to the aldehyde and aminothiol [8]. Simple oxidative transformations of the thiazolidine skeleton lead to a number of scaffolds namely, *N*-oxides, 2- or 3-thiazolines, and thiazoles. Oxidation can also occur at sulfur (S1), to afford sulfoxide or sulfone derivatives [7]. Thus thiazolidine is amenable to chemo selective reactions leading to different structural entities (Fig 2).

Figure 2

2.2

Thiazolidine-4-carboxylic acids

Discovery of thiazolidine-4-carboxylic acids was made accidentally by Birch and Harris [9] during the study of effect of formaldehyde on the titration curves of amino acids. Later on Schubert [10] has explained the formation of thiazolidine-4-carboxylic acid by condensation of cysteine and formaldehyde followed by intramolecular cyclization. Accordingly, a large number of thiazolidine-4-carboxylic acids can be synthesized by condensation of aldehydes and ketones with cysteine and/or pencillamine as shown in Scheme 3.

Scheme 3

Although cyclization can take place in many a ways, according to Kallen [11] most preferred pathway involves imine formation followed by intramolecular cyclization. During the course of cyclization a new chiral center at C-2 is created thereby giving rise to diastereomeric mixture namely 2*R*, 4*R* and 2*S*, 4*R*. An interesting situation arises when the reactant aldehyde is also chiral. The stereochemistry at the newly formed centre is controlled by the stereochemistry of the aldehyde [12]. In view of biological importance of thiazolidine, Patek et al

have reported a solid phase synthesis protocol (Scheme 4) [13]. This enables the synthesis of compound libraries for quick lead optimization.

Scheme 4

2.3

Properties of thiazolidine-4-carboxylic acids

The unsubstituted thiazolidine-4-carboxylic acid i.e. thioproline is remarkably stable towards both alkali as well as acid while the 2-substituted thiazolidine-4-carboxylic acids are unstable under similar conditions [14]. However the N3-substituted thiazolidines are stable in solution because the substituent group prevents the ring opening. The parent compounds are generally solids and exhibit poor solubility in different solvents whereas N3-substitution increases solubility in most of the organic solvents. The ring heteroatoms (S1 and N3), C-2 and the C4-pendant carboxylic group are amenable to further chemical transformation in generating libraries of compounds.

2.4

Thiazolidin-4-ones

Several protocols for the synthesis of thiazolidin-4-ones are available in the literature [15-23]. Essentially they are three component reactions involving an amine, a carbonyl compound and a mercapto acid. The process can be either a one-pot three-component condensation or a two-step process as shown in Scheme 5. The reaction has been suggested to proceed via imine formation followed by the attack of sulfur nucleophile on the imine carbon. The last step involves intramolecular cyclization with the elimination of water to give thiazolidin-4-ones. This step appears to be critical for obtaining high yields. Therefore, variations have been affected in this step to facilitate removal of water. Most commonly used protocols employ azeotropic distillation, molecular sieves, and

use of other desiccants like anhydrous zinc chloride [24], sodium sulphate [25] or magnesium sulphate [26]. These protocols require prolonged heating at 70-80 °C for 17-20 hrs and give moderate to good yields.

Scheme 5

More recently, an improved protocol has been reported wherein N, N'-Dicyclohexylcarbodiimide (DCC) or 2-(1H-Benzotriazo-1-yl)-1,1,3,3-tetramethyluraniumhexafluorophosphate (HBTU) (Scheme 6) is used as a dehydrating agent to accelerate the intramolecular cyclization resulting in faster reaction and improved yields [27,28]. The DCC / HBTU mediated protocol has the advantage of mild reaction conditions, very short reaction time and product formation in almost quantitative yields. More importantly, yields of the thiazolidinones are independent of the nature of the reactants. This modification is compatible with solid phase combinatorial approach to generate library of compounds.

Scheme 6

Recently, Holmes et al have reported the solution and polymer-supported synthesis of 4-thiazolidinones and 4-metathiazinones derived from amino acids (Scheme 7) [29]. A three-component condensation of an amino ester or resin-bound amino acid (glycine, alanine, β -alanine, phenylalanine and valine) an aldehyde (benzaldehyde, *o*-tolualdehyde, *m*-tolualdehyde, *p*-tolualdehyde and 3-pyridine carboxaldehyde) and an α -mercapto carboxylic acid has led to the formation of five and six membered heterocycles. In amino acids, the carboxylic acid function has served as anchor group for attachment to the site of support. The condensation of this support bound amine with several aldehydes and mercapto acetic acids in a one-pot reaction for 2 hr at 70°C with removal of water has afforded the desired products. For successful completion of reaction, they have employed 15 to 25 equiva. of reagent solution relative to resin loading.

Scheme 7

A special situation arises when mercaptosuccinic acid is used as a mercapto component. Both the carboxyl functions are prone to nucleophilic attack by the imine nitrogen and give rise to five (I) as well as six membered (II) cyclic structures. Subsequently Poop et al, have shown by x-ray crystal structure analysis that a five membered (III) cyclic structure is preferred over the six membered (IV) cyclic structures (scheme 8) [30].

Scheme 8

2.5

Properties of thiazolidine-4-ones

The N3-unsubstituted thiazolidinones are usually solids, often melt with decomposition, but substitution at this position lowers the melting point. The thiazolidinones that do not carry N3-aryl or higher alkyl substitution are partially soluble in water and can be recrystallized from water. Thiazolidinones undergo a limited number of chemical transformations shown in Scheme 9. The methylene carbon atom at the 5-position of thiazolidinone possesses nucleophilic activity and can attack on an electrophilic center. Most frequently the reaction occur in the presence of a base and the anion of the 4-thiazolidinone attacking species as shown in scheme 9 [31,32].

Scheme 9

The carbonyl group of 4-thiazolidinone is highly unreactive. But in a few cases it undergoes certain reactions for example 4-thiazolidinone on treatment with Lawesson's reagent gives corresponding 4-thione derivatives in almost quantitative yields [33]. Oxidation of 2,3-disubstituted-4- thiazolidinone with hydrogen peroxide in acetic anhydride and acetic acid [34] or by potassium permanganate in aqueous acetic acid solution [35] results in the corresponding sulfones. On the other hand the oxidation with hydrogen peroxide in aqueous acetic acid solution gives corresponding sulfoxide [36]. A more detailed account

of the chemistry and biological activities of thiazolidine-4-carboxylic acids can be found in the earlier reviews [37-40].

The diverse biological activities exhibited by the thiazolidines can be broadly classified into those affecting the host biology including the metabolic disorders and those affecting the parasite function in the host. The former activity profile relates mostly to the inflammatory, ulceration, allergy, and blood coagulation processes and to the metabolic disorders such as obesity, diabetes and associated pathological manifestations. The latter category of activities is mostly concerned with the human immunodeficiency virus (HIV) and fungi. Apart from these some QSAR reports on the insecticidal activity of thiazolidines have also been included to widen the scope of this article.

3.0

QSAR and Modeling studies

QSAR and modeling studies comprise of two basic components. Of which, the first one corresponds to the measurements (parameterization) of the chosen object in numeric or boolean form and the other one addresses the development of relational expressions between or among the measurements made on the objects. The reviewed studies have used different physicochemical, quantum chemical, topological and topographical descriptors from various sources such as Hansch and Leo's monograph [41], Molecular Orbital Partial Atomic Charge (MOPAC) [42], ChemDraw's property/descriptor database [43], Comprehensive Descriptors for Structural and Statistical Analysis (CODESSA) [44,45], Molecular Electronegativity Distance Vector (MEDV-13) [46], and DRAGON [47] etc for the parameterization of the chemical structure. The 2D-QSAR results presented in the review have been brought out using different statistical procedures and programs namely, simple Multiple Linear Regression (MLR), Principle Components in multiple linear Regression (PCR), Partial Least Square (PLS) [48], Genetic Function Approximation (GFA) [49], Genetic partial least squares (G/PLS) [50], Combinatorial Protocol in Multiple Linear Regression (CP-MLR) [51], Variable Selection and Modeling method based on Prediction (VSMP) [52], Artificial Neural Network (ANN) [53-55], discriminant and cluster analysis.

The 3D-QSAR results explained in this article have come from the application of Comparative Molecular Field Analysis (CoMFA) [56], Comparative Molecular Similarity Analysis (CoMSIA) [57], Molecular Shape Analysis (MSA) [58,59], Molecular Field Analysis (MFA) [60] and steric and electrostatic field interactions in Receptor Surface Model (RSM) [61,62] techniques on the datasets. Apart from these, results of some interesting pharmacophore identification [63,64], virtual screening [65,66], docking [67,68] and X-ray crystallographic studies have been discussed to give the complete picture of 'virtual to wet chemistry'. All these 3D studies have been carried out using various commercial software namely Insight II [69], SYBYL [70], MOE [71]. All these packages use 'built-in' statistical techniques for the assessment of significance of the developed models. They are similar to one or more statistical procedures of 2D-QSAR. Most of the 2D and 3D results presented in this review have been validated through various techniques such as leave one out, leave many out and external test sets. However, to maintain uniformity and conciseness, only limited statistical measures of the goodness of fit of regression equations have been presented. In all regression equations, n is the number of compounds in the dataset, r is the correlation coefficient, Q^2 is cross-validated r^2 from leave-one/many out procedure, s is the standard error of the estimate, and F is the F-ratio between the variances of calculated and observed activities. The values given in the parentheses of regression equation are the standard errors (without arithmetic sign) or 95% confidence limits (with \pm arithmetic sign) of the regression coefficients. A mention is made about the nature of each QSAR study /methodology along with the results. The contributing or modeling descriptors for each case have been identified and discussed along with the modeling equations. In the succeeding sections of this article QSAR studies on the diverse biological responses elicited by the various compounds anchored via thiazolidine skeleton system have been described. Hereafter 'thiazolidine' has been used to broadly address all nitrogen-sulfur containing five-membered heterocyclic systems with different oxidation states. However, care has been taken to specify the name of the chemical congener(s) under each investigation.

3.1

Anti-Inflammatory Agents

3.1.1

Cyclooxygenase Inhibitors

Thiazolyl and benzothiazolyl derivatives are known for their anti-inflammatory, analgesic and antipyretic activities [72- 77], for example Meloxicam (Fig. 3) is a known non-steroidal anti-inflammatory agent with thiazolyl moiety as part of its scaffold [78]. These non-steroidal anti-inflammatory agents are known to act through the inhibition of cyclooxygenase (COX) involved in the arachidonic acid pathway. In this contest, the development of 2-[4-(thiazole-2-yl) phenyl]propionic acid derivatives (Fig. 3, Table 2) as anti-inflammatory agents has its roots in the sub-structural units of indomethacin, clidanac and pirofen (Fig. 3) [79,80].

Figure 3

Table 2

Naito and co-workers investigated the COX inhibitory activity of these 2-[4-(thiazole-2-yl) phenyl]propionic acid derivatives (Fig. 3, Table 2) in terms of different physicochemical and structural descriptors of the substituent positions (R_1 , R_2 and R_3) [80]. The following equations show the correlation of the activity with these descriptors in different groups of compound.

(Table 2; compounds 1-11)

$$pI_{50} = 1.08(0.50)\pi(R_1) + 1.18(0.97)\sigma_1(R_1) + 5.64$$

$$n = 11, r = 0.89, \quad s = 0.28, \quad F = 15.81 \quad (1)$$

(Table 2; compounds 1, 12-25)

$$pI_{50} = -4.10(2.75) \sigma_R(R_2) - 0.72(0.28)\Delta L(R_2) + 0.43(0.39)\pi(R_2) + 5.81$$

$$n = 15, r = 0.91, \quad s = 0.46, \quad F = 17.90 \quad (2)$$

$$pI_{50} = 1.03(0.42) \pi(R_1) - 4.48(1.64)\sigma_R(R_2) - 0.86(0.13) \Delta L(R_2) + 0.44(0.27) \\ \pi(R_{2,3}) - 0.40(0.26) \Delta L(R_3) - 1.48(0.52)I(\text{iso}) + 6.11$$

$$n = 45, r = 0.95, \quad s = 0.38, \quad F = 53.97 \quad (3)$$

Equation 1 correlated the activity of these compounds in terms of their R_1 substituent (Table 2; compounds 1-11). This has suggested that higher hydrophobicity and electron-withdrawing properties of R_1 substituent would lead to better activity [80]. Equation 2 has presented the requirements of R_2 substituent (Table 2, compounds 1, 12-25) in terms of the STERIMOL length parameter (ΔL) [81]. It has suggested that electron releasing and hydrophobic substituents with small length would be conducive at R_2 position for better inhibitory activity. Equation 3 is a collective model of all the compounds together (Table 2) and represent the influence of R_1 , R_2 and R_3 substituents on the activity. In this, $\pi(R_{2,3})$ and $I(\text{iso})$ have represented the sum of the hydrophobic effects of R_2 and R_3 substituents and an indicator variable defined to account for the *iso*-propyl group at R_2 position of the compounds, respectively. The negative regression coefficient of $I(\text{iso})$ in this equation has led to suggest the steric restriction at the receptor site for the compounds carrying α -branched alkyl groups as R_2 substituents. The larger negative coefficient of ΔL term of R_2 (compared to that of R_3) has further confirmed this effect. In summary, this study has indicated that the activity prefers hydrophobic substituents for R_1 , R_2 and R_3 positions of these compounds (Fig. 3). It has also suggested that electron withdrawing groups are favorable for R_1 and electron rich groups are favorable for R_2 . In addition to these, steric restrictions have been found to operate in case of R_2 and R_3 groups.

Both COX-1 and COX-2 enzymes in the arachidonic acid pathway are known to play a role in the inflammatory process. However, the selective inhibition of COX-2 leads to the reduction of the inflammation without any risk of ulceration and bleeding of the stomach or intestinal tract, a side effect commonly associated with most of the non-selective anti-inflammatory drugs. This has made COX-2 as an attractive target for many researchers to investigate the structural requirements of its inhibitors. In pursuit of this goal Liu et al. have carried out a QSAR study on the COX-2 inhibitory activity of indomethacin (Fig 3), SC-58125, NS-398 (Fig. 4) together with some thiazolone and oxazolone derivatives (Fig 4, Table 3) with the MEDV-13 (molecular electronegativity distance vector based on 13 atomic types) descriptors [82]. These descriptors represent the electrotopological state of the molecules [83, 84]. In this study good predictive models (Eq.4) have been obtained for the COX-2 inhibitory activity of these compounds in terms of the MEDV-13 descriptors.

Figure 4

Table 3

$$\text{pIC}_{50} = 0.089 (0.013) \mathbf{x}_1 + 0.126(0.029) \mathbf{x}_7 + 0.175(0.028) \mathbf{x}_{29} + 0.706(0.178) \mathbf{x}_{52} + 5.944$$

$$n = 21, r = 0.925, Q^2 = 0.783, s = 0.283, F = 23.62 \quad (4)$$

In this equation \mathbf{x}_1 , \mathbf{x}_7 , \mathbf{x}_{29} and \mathbf{x}_{52} are part of MEDV-13 descriptors of the compounds. However, no interpretation has been provided, in terms of properties of participating descriptors, to diagnose the inhibitory behavior of the compounds. In a different study, Vigorita et al have used the docking experiments to analyze and understand the configuration preferences of the optical isomers of 3,3'-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4-thiazolidinones (Fig. 5) in relation to the available structures of COX-1 and COX-2 enzymes [85].

Figure 5

These compounds have two equivalent chiral centers (C-2 and C-2') (Fig. 5). They have been pharmacologically evaluated as racemic mixture (2R, 2'R / 2S, 2'S) and as meso isomers (2R, 2'S). In the docking experiments the differences between the interaction modes of *RR*, *SS* and *RS* isomers have been analyzed using the ligand internal energies and enzyme/ligand (E/L) interaction energies of the respective isomers with the available structures of COX-1 and COX-2 enzymes (Fig. 6, Table 4) [85].

Figure 6

Table 4

This study has suggested the features of COX catalytic sites vis-à-vis the interaction modes of *RR*, *SS* and *RS* enantiomers of 3,3'-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4-thiazolidinones with the active sites of the enzyme [85]. A comparison of the E/L interaction energy of these enantiomers has indicated that *SS* isomer has the highest affinity for the COX-2 (Table 4). Further, the internal energy of the *SS* isomer has been reported to be favorable for binding into the COX-2 catalytic site than that into the COX-1 (Table 4). It has been shown that the *SS* enantiomer has the capability to deeply penetrate into the catalytic site of the COX-2 (Fig. 6a) by assuming an extended conformation. It has also highlighted the ligand's electrostatic and van der Waals (VdW) interactions with several residues (Arg120, Val116, Ser530 and Tyr385) of enzyme's binding site. However, in case of the COX-1, it has been reported that the ligand has to undergo an unfavorable folding (dihedral angle of N-C-C-N is -134.85°) for binding to the COX-1 site (Fig. 6b). Also, in this situation, one of the thiazolidinone moieties (moiety 'A' in Fig. 5) of the ligand has been reported to be in the proximity of a hydrophobic pocket delimited by residues Ile523, Tyr355 and Phe518. All these findings have prompted Vigorita et al to suggest the favorability of *SS* enantiomers for binding to the COX-2 catalytic site [85].

3.1.2

Nitric oxide synthase inhibitors

Thiazolidines are also known to interfere in the inflammatory process through Nitric oxide (NO) and glycosaminoglycans (GAGs) pathways [86,87]. During the inflammation process, the increased activity of matrix metalloproteinases (MMPs) causes the release of GAGs, followed by the cleavage of collagen and proteoglycans, the primary components of the cartilage. Also, in a feed-back mechanism, the NO, from the NO synthases, determines the inhibition of GAGs and stimulation of chondrocytes production and thereby the levels of MMPs [88-90]. In this background Panico et al. have quantitatively analyzed some 4-alkyl/aryl-2-(N-substituted aminoalkylamido) thiazoles (Fig. 7, Table 5) for their effect on NO production and GAGs release [87].

Figure 7

Table 5

For these compounds (Table 5) the following equations have been developed to explain their NO and GAGs inhibitory activity.

$$\text{NOinh} = -196.156(94.346)q_{NR1} + 4.742 (1.377)pKa - 57.001$$

$$n = 9, \quad r = 0.850, \quad s = 5.383, \quad F = 7.83 \quad (5)$$

$$\text{GAG} = 0.035(0.013)P + 3.381(0.734)pKa - 19.241$$

$$n = 9, \quad r = 0.883, \quad s = 2.508, \quad F = 10.68 \quad (6)$$

These equations have led to suggest that the pKa is the major descriptor for deciding the NO and GAG inhibitory activities of the compounds under investigations. As the R₁ substituent in these compounds is primarily responsible

for the basicity, pyrrolidine moiety has been suggested as the most preferred group for this position for better activity. Apart from the pKa, the charge at NR₁ (qNR_1) and the parachor (P) of the molecules have been found to influence the activities [87].

A different series of 4-alkyl/aryl-2-(N-substituted aminoalkylamido) thiazoles (Fig. 8, Table 6) have been analyzed by Litina et al. for their anti-inflammatory activity in terms of the inhibition of carrageenan mice paw edema (%CPE) [90]. In this study the activity (%CPE) has been correlated with several physicochemical and indicator parameters of these compounds (Table 6) [91].

Figure 8

Table 6

$$\log (\%CPE) = 0.078 (0.054) \text{ clog } D_{7.4} - 0.017 (0.013) \text{ clog } D_{7.4}^2 + 0.029(0.008) SURF + 0.060$$

$$n = 16, r = 0.711, \quad s = 0.107 \quad F = 4.09 \quad (7)$$

(compounds excluded: 11–15 and 22–26)

$$\log (\%CPE) = 0.107 (0.031) \text{ clog } D_{7.4} - 0.027 (0.007) \text{ clog } D_{7.4}^2 + 0.043 (0.005) SURF - 0.681$$

$$n = 13, r = 0.945, \quad s = 0.052, \quad F = 24.95 \quad (8)$$

(compounds excluded: 1, 6, and 13 11–15 and 22–26)

In deriving these equations several compounds have been excluded as outliers. The parabolic relation in $\text{clog}D_{7.4}$ has suggested 1.98 as the optimum hydrophobicity for the easy transportation and rapid delivery to the target biomacromolecule. The positive regression coefficient of the parameter surface tension ($SURF$) has been interpreted as the anti-inflammatory activity of the test compound increases linearly with the increase in its surface tension. On the basis

of the above results it has been concluded that the pharmacokinetic properties of these compounds play a key role in their anti-inflammatory activity. These findings have been found to be in good agreement with previously reported results concerning other non-steroidal anti-inflammatory drugs (NSAIDs) [92].

3.1.3

Adenosine receptor antagonists

Thiazoles and related analogues have been indicated to influence the inflammatory processes through their antagonistic activity at the adenosine receptors [93-95]. Among the various adenosine receptors, the subtypes A₁ and A₃ have been indicated in the inflammation, asthma [96,97], glaucoma [98], myocardial and cerebral ischemia [99-102]. A systematic template search of quinazolines, isoquinolines and other prototypes has resulted in the induction of thiazole class as adenosine A₃ receptor antagonists (Fig. 9) [93].

These findings have prompted Jung et al. to explore several thiazole and thiadiazole derivatives as potent human adenosine A₃ receptor antagonists (Fig. 9, Table 7) [95]. Using the principal component factor analysis (FA) and genetic function approximation (GFA) techniques, Bhattacharya et al. have quantitatively analyzed the adenosine A₃ receptor antagonistic activity of these compounds (Fig. 9, Table 7) with the quantum chemical descriptors (Wang-Ford charges from AM1 method), hydrophobicity (logP) and some indicator parameters [103]. In this study, the Eq. 9 has emerged from the factor analysis and Eqs. 10 and 11 have emerged from GFA technique.

Figure 9

Table 7

$$\text{pKi} = -3.951(2.415)q_2 - 2.623(2.136)q_5 + 2.441(1.489)q_7 - 0.275(0.261)\log P - 1.498(0.763)I_{\text{OBu}_t} + 0.895(0.614)I_{\text{Me}_t} + 4.030$$

$$n=30, r= 0.893, Q^2 = 0.689, s = 0.483, F = 15.0 \quad (9)$$

$$\text{pKi} = -1.940(2.072)q_2 - 11.413(3.878)q_8 - 13.611(5.005)q_9 - 0.038(0.029)(\log P)^2 - 1.556(0.722)I_{\text{OBu}_t} + 3.083$$

$$n=30, r = 0.902, Q^2=0.753, s = 0.452, F = 21.0 \quad (10)$$

$$\text{pKi} = -1.932(2.150)q_2 - 1.413(4.012)q_8 - 13.741(5.189)q_9 - 0.311(0.260)\log P - 1.518(0.747)I_{\text{OBu}_t} + 3.686$$

$$n=30, r = 0.896, Q^2=0.739, s = 0.465, F = 19.6 \quad (11)$$

The equation from factor analysis (Eq.9) has explained the activity in terms of $\log P$, I_{Me_t} , (an indicator parameter defined for the presence of methyl or ethyl substituent at R position), I_{OBu_t} (an indicator parameter defined for the presence of *tert*-butyloxy group at R position) and Wang-Ford charges (q_2 , q_5 and q_7) of atoms C2, C5 and C7. This has suggested that less hydrophobic compounds with methyl or ethyl and without *tert*-butyloxy group at R position would be favorable for the adenosine A₃ receptor antagonistic activity [103]. The GFA technique has resulted in equations with improved statistics (Eq. 10 and 11). These equations have suggested that less hydrophobic compounds without a *tert*-butyloxy group at R position would be better for the binding affinity at the receptor. Moreover, the Wang-Ford charges at atoms C2, X8 and S9 have been identified as contributing ones to modulate the binding affinity of these compounds. In this the Wang-Ford charges of X8 and S9 are from part of the thiazole/ thiadiazole nucleus and signify their role in deciding the activity of these compounds.

The adenosine A₃ receptor antagonistic activity of these compounds have been further analyzed [104] in 3D-QSAR using molecular shape analysis (MSA) and molecular field analysis (MFA) techniques in Cerius2 (version 4.8) software [50]. In this, Jurs atomic charge descriptors have been used for the MSA study and H⁺ point charges and CH₃ derived steric fields have been used for the MFA study. In this 3D-QSAR study, MSA has resulted in Eqs. 12 and 13 and MFA has led to Eq. 14.

$$pC = 0.140(0.052)JursPPSA_3 + 61.920(20.616)Jurs\ RNCG - 1.024(0.766)JursRPCS - 0.006(0.004)JursSASA + 0.006(0.004)Energy + 1.645(1.022)Fo - 8.735$$

$$n = 30, r = 0.901, Q^2 = 0.705, s = 0.215, F = 16.6 \quad (12)$$

$$pC = 0.130(0.048)JursPPSA_3 + 61.291(20.009)Jurs\ RNCG - 1.056(0.749)JursRPCS + 0.007(0.004)Energy + 1.701(0.988)Fo - 0.001(0.000)PMI_mag - 10.180$$

$$n = 30, r = 0.907, Q^2 = 0.700, s = 0.203, F = 17.8 \quad (13)$$

$$pC = -0.050H^+/283 - 0.028H^+/366 - 0.031H^+/427 - 0.019H^+/448 - 0.054H^+/466 - 0.052H^+/534 - 0.030H^+/608 - 0.021H^+/618 - 0.020H^+/687 + 0.033H^+/757 - 0.010CH_3/417 - 0.052CH_3/474 + 0.025CH_3/529 - 0.022CH_3/756 + 5.59$$

$$n = 30, r = 0.990, Q^2 = 0.716, s = 0.500 \quad (14)$$

The equations from MSA (Eqs. 12 and 13) have explained the activity in terms of atomic charge weighted positive surface area (JursPPSA_3), charge of the most negative atom divided by the total negative charge (JursRNCG), total molecular solvent-accessible surface area (JursSASA), relative positive charge surface area (JursRPCS), conformational energy of the molecules (Energy), partial moment of inertia, energy of the most stable conformer (PMI_mag) and the ratio of common overlap steric volume to volume of individual molecules (Fo). Based on the 3D-QSAR equation from the MFA the authors could explain 96.1% variance in the activity with cross-validated r^2 as 0.716. In this equation the numbers suffixed to H⁺/ and CH₃/ respectively, notify the significant polar and steric grid locations involved in modeling the adenosine A₃ receptor antagonists. From these studies they have concluded the importance of Jurs descriptors and the interaction energies of various molecular field grid locations in modeling the activity of these analogues [104].

Borghini et al. [105] have also carried out a QSAR study on the adenosine A₃ receptor antagonistic activity of these compounds (Fig. 9, Table 7) with the CODESSA descriptors. For this study, 26 compounds have been taken in the training set for the model development and 6 compounds have been put in the test set to verify the developed model. This study has resulted in the following correlation (Eq. 15) for the adenosine A₃ receptor antagonistic activity of the compounds in terms of electrostatic descriptors namely ‘HACA-2/TMSA’ (ratio of total charge weighted hydrogen-acceptor charged surface area and total molecular surface area), MPCS (minimum partial charge on S atom) ‘WNSA-3’ (total surface weighted partial negative surface area) and RNH (number of H atoms at the position R).

$$\text{pKi} = 17296(260)\text{HACA-2/TMSA} + 22.73(4.44)\text{RNH} + 46.56(10.83)\text{MPCS} - 0.382(0.009)\text{WNSA-3} - 6.17$$

$$n = 26, r = 0.840, Q^2 = 0.548, s = 0.559, F = 12.23 \quad (15)$$

This equation has also suggested the importance of polarity/ partial charges on the heteroatoms of thiazole moiety for adenosine A₃ receptor antagonistic activity. Based on this, it has been suggested that thiadiazoles capable of accepting hydrogen bonds and carrying small non-polar alkyl substituent at the position R, would be better for binding to the adenosine A₃ receptor [105].

With the CODESSA descriptors, Borghini et al [105] have also carried out a QSAR study on the adenosine A₁ receptor antagonistic activity of another series of thiazoles/ thiadiazoles (Fig. 9) [93, 94]. In this, 27 compounds have been included for training the model and 7 compounds have been used for testing the model (Fig. 9, Table 8). The following three descriptors model in terms of MPCN (minimum partial charge on N atom), ZXS/ZXR (ZX Shadow/ZX Rectangle) and PP/D² (polarity parameter/square distance) has been derived to explain the affinity of these compounds to adenosine A₁ receptor.

Table 8

$$\text{pKi} = 155.1(17.38)\text{MPCN} + 3.86(0.99)\text{ZXS/ZXR} + 2.12(1.11)\text{PP/D}^2 + 17.28$$

$$n = 27, r = 0.901, Q^2 = 0.742, s = 0.382, F = 33.15 \quad (16)$$

In equation 15, the coefficient of ZXS/ZXR has suggested a preference for an aromatic substituent for R group. The positive regression coefficients of MPCN and PP/D² are favor of increase in the partial charge and polarity in the compounds for better activity. This has prompted to suggest that thiadiazole derivatives with aromatic substituents would enhance the affinity of the compounds for the adenosine A₁ receptor.

3.1.4

Histamine (H₁) antagonists

Thiazolidines are known to show their action on histamine receptors. The geometrical similarity between 2-aryl-3-[3-(N,N-dimethylamino)propyl]-1,3-thiazolidin-4-ones and different histamine (H₁) antagonists such as bamipine, clemastine, cyproheptadine, triprolidine, promethazine, chlorpheniramine and carbinoxamine (Fig. 10) [106, 107] has prompted Diurno et al to evaluate these compounds for the antihistaminic activity [108]. Singh and co-workers have investigated the QSAR of the antihistaminic (H₁) activity of these 2,3-disubstituted thiazolidin-4-ones (Table 9) with the hydrophobicity (π), molar refractivity (MR), Hammett's sigma (σ) constant, dipole moment (μ) and Swain and Lupton's polarity (ΣF) and resonance (R) constants of the substituent groups [109]. In this study the antihistaminic (H₁) activity of these compounds has been found to be best explained by ΣF and π_4 descriptor-combinations of R substituent groups (Eq. 17) [109].

Figure 10

Table 9

$$pA_2 = -2.753(0.715) \Sigma F + 0.907 (0.297) \pi_4 + 7.267$$

$$n = 15, r = 0.832, \quad s = 0.672, \quad F = 13.54 \quad (17)$$

$$pA_2 = -2.573(0.346) \sum F + 1.019(\pm 0.148) \pi_4 + 7.412$$

$$n = 13, r = 0.961, \quad s = 0.320, \quad F = 60.70 \quad (18)$$

In deriving equation 18, compounds 3 and 6 (Table 9) have been excluded as they were found to be outliers in the study. From this, they have concluded that hydrophobic substituent at 4-position of phenyl ring and cumulative negative polar effects of all the substituents in the phenyl group are advantageous for antihistaminic activity [109].

Agrawal et al have studied the anti-histaminic activity of these 2,3-disubstituted thiazolidin-4-ones analogues (Table 9) with graph theoretical indices and discovered the following equation for the activity in terms of rooted Wiener index (W_w), rooted Szeged index (Sz_w), molecular redundancy index (MRI) and an indicator variable I_{p_1} (for the p-alkyl of the aryl moiety) [110].

$$pA_2 = 99.776 \text{ MRI} + 0.989 \text{ Sz}_w - 1.414 \text{ W}_w + 0.859 \text{ I}_{p_1} - 34.882$$

$$n = 11, r = 0.980, \quad s = 0.228, \quad F = 37.13 \quad (19)$$

However, in deriving this equation four compounds (Table 9, compounds 3, 6, 7 and 15) have been excluded from the study. Between these two studies, the model (Eq.18) proposed by Singh et al [109] is far superior when compared to the later one (Eq. 19) [110].

In another interesting study, considering the importance of asparagine, aspartic acid, threonine and lysine in the binding of agonists/ antagonists to histamine (H_1) receptor, Brzezinska and co-workers [111,112] have quantitatively investigated the antihistaminic (H_1) activity of substituted thiazoles and benzthiazole derivatives [113-115] (Fig. 11, Table 10) using the logP and reverse and normal phase thin layer chromatographic (TLC) parameters (R_m values) generated through impregnating the TLC plates with these selected amino acids. The idea

behind impregnating the TLC plates with amino acids was to assess their contribution in the binding affinities at the receptor site and in turn use them in modeling the activity of the compounds. Accordingly, the R_m values of the compounds have been measured under different chromatographic environments [111,112]. Following are the representative QSAR equations of the antihistaminic (H_1) activity in the reverse and normal phase TLC studies, respectively, of these compounds.

Figure 11

Table 10

reverse phase TLC model

$$pA_2 = -1.27(0.23) S2/C + 9.59(2.60)C-S6 + 0.63(0.09)\log P + 3.96$$

$$n = 18, r = 0.94, \quad s = 0.289, \quad F = 35.11 \quad (20)$$

normal phase TLC model

$$pA_2 = 1.16(0.34) S4 + 0.16(0.03)S7/C + 0.54(0.07)\log P + 4.16$$

$$n = 18, r = 0.95, \quad s = 0.254, \quad F = 47.04 \quad (21)$$

The terms S2, S4, S6, S7 and C represent, respectively, the chromatographic environment(s) formed by combinations of asparagine, lysine, asparagine+lysine, asparagine+aspartic acid+ threonine and/ or control (without amino acids). In these equations S2/C, S4, C-S6 and S7/C refer to the R_m values (independent descriptors) of corresponding chromatographic environments (impregnation) reflected in modeling the antihistaminic (H_1) activity. These studies have highlighted the importance of overall hydrophobicity of the compounds in deciding the activity. They also have quantified the interaction of selected amino acids with the compounds. It has further suggested that the normal phase TLC parameters have modeled the activity better than that of reverse phase TLC parameters. This study has opened up a novel way for generating the receptor

directed interaction information in terms of amino acids for modeling the antihistaminic (H_1) activity of these compounds. One can adapt to this kind of procedure for the study of other receptors also.

3.1.5

H⁺K⁺-ATPase Inhibitors

Thiazolidines have been reported to be a core scaffold for the antiulcer compounds. La Mattina et al. have evaluated a series of one hundred and twenty eight compounds belonging to 4-substituted-2-guanidino thiazoles (Fig. 12) against gastric hydrogen-potassium stimulated adenosine triphosphatase (H^+K^+ -ATPase), a therapeutic target of anti-ulcer drugs [116].

Figure 12

Goel and Madan [117] have investigated the SAR of the antiulcer activity of these compounds with the Wiener's topological index (Wiener number of chemical graph, $W(G)$) [118] and first order molecular connectivity index ($^1\chi$) [119] using typical classification procedure. In case of the Wiener's topological index, the compounds have been correctly classified into active and inactive groups to the order of 89%. A Wiener index value in the range of 391 to 540 has been observed to be associated with the active analogues. In case of molecular connectivity index the overall accuracy of prediction has been reported as 88%. And, the activity has been found to be associated with the $^1\chi$ values in the range of 5.75 to 7.20 [117]. This approach is very handy and quick for the screening of large databases.

Borges and Takahata have studied the QSAR of a different series of 4-indolyl, 2-guanidinothiazole derivatives (Fig. 13; Table 11) for their H^+K^+ -ATPase inhibitory activity using ninety-four quantum chemical descriptors generated for this purpose [120].

Figure 13

Table 11

They have adopted partial least square (PLS), principal component regression (PCR) and back propagation neural network (BPN) methods for the derivation of the regression models. Among these approaches, the activity has been found to be best explained in the PLS analysis with five latent variables. In terms of the whole molecular structure, this has led to suggest that the energies of the highest occupied molecular orbitals -9, -8, -7, -5, -3, -2 and -1 ($\epsilon_{\text{HOMO-9}}$, $\epsilon_{\text{HOMO-8}}$, $\epsilon_{\text{HOMO-7}}$, $\epsilon_{\text{HOMO-5}}$, $\epsilon_{\text{HOMO-3}}$, $\epsilon_{\text{HOMO-2}}$, $\epsilon_{\text{HOMO-1}}$) the dipole moments along x- and z-axis (μ_x , μ_z) and quadrupole moments yy, zz and xz (Quad_{yy} , Quad_{zz} and Quad_{xz}) are important contributors to model the activity. In terms of individual atomic centers of these analogues, the study has identified the electron densities F_3^T , F_6^T , F_4^H , F_9^H , F_4^L , F_6^L , F_7^L , F_8^L , F_{11}^T , F_{13}^H , F_{14}^H , F_{12}^L , F_{13}^L , F_{14}^L and F_{15}^L and the charges Q_2 , Q_3 , Q_5 , Q_6 , Q_{12} and Q_{18} (the subscript numbers correspond to the atom identification number as shown in Fig. 13; the super scripts T, H and L represent Total, HOMO and LUMO, respectively) as important to explain the activity of the analogues. This study has explained the activity in terms of a detailed electronic profile of the compounds. However, these results are far more sophisticated and at the same time too complex to comprehend when compared to that of Goel and Madan's investigations involving Wiener's and Chi indices [117].

3.1.6

Antiepileptic agents

Thiazolidines/ thiazoles in fusion with other aromatic systems are also potential bioactive scaffolds. Riluzole (Fig. 14) - a benzothiazole analogue - is known to intervene in epilepsy, a cerebral disorder of central nervous system, via a glutamatergic mechanism [121]. The anticonvulsant activity of riluzole has been attributed to its direct action on the voltage-dependent sodium channels [122]. Hays et al have investigated the QSAR of the anticonvulsant activity of substituted 2-benzothiazolamines (Fig. 14, Table 12) with hydrophobicity (π),

molar refractivity (MR), Hammett's sigma (σ) and Swain and Lupton's polarity (\mathcal{P}) and resonance (\mathcal{R}) constants and an indicator parameter (45SUBST) describing the importance of the 4 and/or 5 substituents [123]. This study has resulted in the following equation to explain the variation in the anticonvulsant activity of these analogues.

Figure 14

Table 12

$$-\log IC_{50} = 0.57 (0.12) \pi - 0.90(0.19) 45SUBST - 0.45 (0.14)MR + 0.92(0.38)\mathcal{R} + 4.57$$

$$n = 30, r = 0.794, \quad s = 0.480, \quad F = 10.80 \quad (22)$$

Based on this it has been suggested that increase in lipophilicity (π), decrease in size (MR), increase in resonance effect (\mathcal{R}) and the absence of 4 or 5 substitution of benzothiazolamine ring system would be favorable for anticonvulsant activity. This has been presented as an example of QSAR in fused systems. In literature more study reports are available where thiazole moiety has existed as part of the fused ring systems [77].

3.2

Metabolic disorders

3.2.1

β_3 -receptor agonists

Thiazoles have been investigated as potential drug scaffold in the treatment of metabolic disorders such as obesity, diabetes, cataract and thrombosis. They have

been reported to be associated with the β_3 agonist activity (a subtype of β -Adrenergic receptor) through the activation of adenylyl cyclase [124, 125]. This receptor has been implicated in obesity, a condition of abnormal body weight resulting from the accumulation of extra adipose tissue due to a state of positive energy balance characterized by diminished energy expenditure when compared to the energy intake [126]. A systematic exploration involving several imidazolindinone (**a**), imidazolone (**b**), indoline (**c**) and thiazole (**d,e**) derivatives in the stimulation of adenylyl cyclase revealed the advantage of the thiazole derivatives (**e**) over the rest of compounds as β_3 agonists (Fig. 15) [124, 125, 127, 128].

Figure 15

In this context, Hanumantharao et al [129] have carried out a QSAR analysis of the β_3 agonist activity of the thiazole derivatives (**e**) with the molecular descriptors generated from the MOE programme [71]. This has resulted in QSAR models (Eqs. 23, 24) of these compounds in terms of hydrophobicity of VdW surface areas with different polarities (SlogP, SlogP_VSA0 and SlogP_VSA8), electrostatic potential energy (E_ele) and zero order connectivity index (chi0) (Table 13).

Table 13

$$pEC_{50} = 0.266 (0.039) \text{ chi0} + 88.998 (14.954) E_{\text{ele}} - 0.030 (0.006) \text{ SlogP}_{\text{VSA0}} - 3.880$$

$$n = 16, r = 0.936, \quad Q^2 = 0.712, \quad s = 0.191, \quad F = 28.30 \quad (23)$$

$$pEC_{50} = 45.869 (15.591) E_{\text{ele}} + 0.558 (0.071) \text{ SlogP} - 0.003 (0.001) \text{ SlogP}_{\text{VSA8}} - 2.526$$

$$n = 16, r = 0.930, \quad Q^2 = 0.798, \quad s = 0.200, \quad F = 25.36 \quad (24)$$

These equations have led them to suggest that the molecules with the high electrostatic potential energy and lipophilic in nature would be favorable for β_3 -agonist activity.

3.2.2

Neuropeptide Y5 Receptor Antagonists

Other than the β_3 adrenergic receptor agonistic activity, some thiazole derivatives have been reported to show antiobesity activity through Neuropeptide Y5 receptor (NPY5R) [130, 131]. The antagonists of the NPY5 receptor (NPY5R) are known to decrease the food intake in animal models [132]. A virtual screening of a large database with the pharmacophore model (Fig. 16) developed from the hydrophobic and topological similarity of three seed structures (compounds **a-c**, Fig. 16) has paved the way for the discovery of some thiazoles as NPY5R antagonists [130, 133-135].

Figure 16

From this virtual screening, thirty-one compounds (compound **e**, Fig. 16) have been identified to show the activity at $IC_{50} < 10 \mu M$. Among these a thiazole analogue, 2-(3-benzonitrile) amino- 5-benzoyl-thiazole (compound **f**, Fig. 16), has been found to be the most active compound with an IC_{50} of 40nM for the mouse Y5 receptor and even showed activity in a mice feeding model at 10mg/kg via intra peritoneal root [130]. The consensus between the pharmacophore patterns of the compounds **f** and **a** have been highlighted in Fig. 17. In a further SAR study, Guba et al have discovered that electron-withdrawing substituents on aryl moieties would be better for the activity. The position of choice for the substituents groups on the aryl moieties (at 2- and 5- of thiazole), have been found to be *meta* and *ortho*, respectively [130].

Figure 17

In continuation of the search for more active ligands for NPY5 receptor, Nettekoven, Guba and co-workers [131] observed that thiazole **g** derivatives have showed 10 times more affinity than that of thiazole **h** derivatives for the mouse receptor (Fig. 18). This difference in the activity profile of the thiazole isomers **g** and **h** have been explained through the conformational analysis of core scaffolds (Fig 18).

Figure 18

The thiazole isomers **g** and **h** have differed in their minimum energy conformations (Fig.18) due to different torsional angles between the carbonyl function and the heterocycle system. In this, in thiazole **g** isomer a favorable short distance interaction between the carbonyl oxygen and the thiazole sulfur (C=O---S type of interaction), below the sum of van der Waals radii ($<3.3 \text{ \AA}$), has led to an energetically highly preferred conformation. This has found support from Iwaoka et al [136] simulation studies on comparable molecular systems. However, in thiazole **h** isomer the repulsive interaction between the carbonyl oxygen and the thiazole nitrogen has resulted in a high energy bent conformation. The potential energy difference between these conformer states has been found to be of the order of 10 to 7 kJ/mol. This is taken as the reason for the 10-fold increment in the activity profile of thiazole **g** isomer when compared to that of isomer **h**. This study has clearly demonstrated a successful structure-activity investigation involving a lead identification from the virtual screening of totally unrelated seed compounds followed by modification of the generated lead through SAR and conformational studies and finally emerged with far high active compounds compared to the initial leads.

3.2.3

PPAR Agonists

In addition to their affinity to β -Adrenergic and neuropeptide Y5 receptors, thiazolidines are also known to act on peroxisome proliferator-activated receptors (PPARs). In the biological system PPARs regulate the expression of genes involved in the fatty acid and carbohydrate metabolism and in adipocyte differentiation [137]. Among the PPARs, the PPAR γ subtype has received wide attention as its agonists specifically promote insulin action and glucose utilization in the peripheral tissues. Thiazolidinediones (TZDs) are among the early chemical classes reported as the agonists of PPAR γ with high affinity [138, 139]. The SAR studies with the TZD analogues have suggested that an acidic head group with a central spacer group followed by linear lipophilic tail is the primary structural requirements of PPAR γ agonists. The desired linker fragment between the head group (2,4-thiazolidinedione) and the central spacer group has been suggested as methylene moiety. Any deviation in the linker fragment length and α,β -unsaturation in thiazolidinediones have been reported to reduce the PPAR γ activity. For the lipophilic tail a variety of aryl and heteroaryl groups such as, pyridyl (**a**), oxazolyl (**b**, **c**), benzoxazolyls (**d**) have been found to be tolerated with the activity [138, 139, 141-143]. Different alkyl ether, alkyl ketones (**c**), olefin and some cyclic moieties have been investigated as linkers between the central spacer group and the lipophilic tail (Fig. 19). The PPAR γ agonistic response of these compounds has been found to tolerate all these structural variations [140, 144].

Figure 19

The TDZs contain a chiral center at C-5 of the heterocyclic headgroup. The binding assays have indicated that the (*S*)-enantiomer of the TZD binds to the PPAR γ with high affinity [145]. However, under physiological conditions it has been observed to undergo racemization [146]. These studies have provided gross structural requirements of TDZ and related ligands for the PPAR γ agonistic activity. The X-ray studies of the co-crystals of TDZ analogues with different

PPARs have indicated that PPAR γ 's ligand-binding domain (LBD) has an overall similarity with other nuclear receptors [147].

Figure 20

In these X-ray studies, it has been observed that the TDZ moiety binds in helices 3, 4, and 10 and to the activating function-2 by making hydrogen bonds with groups in the side chains of His-449, Tyr-473, His-323 and Ser-289. In the Y-shaped cavity, the agonist's lipophilic tail group has been found to occupy the downward position of 'Y' by interacting with amino acid residues Met-348, Ile-341 and Ile-281 (Fig. 20) [148,149]. Also, Yanagisawa and coworkers molecular modelling studies with the oximes having 5-benzyl-2,4-thiazolidinedione moieties (Fig. 21) [150] as agonists of the PPARs has shown that they occupy similar binding domain of PPAR γ [151]. All these studies have led to suggest that the PPAR γ LBD comprises of thirteen α - helices and a small four-stranded β -sheet. The helices 3, 7 and 10 have been found to form a Y-shaped cavity to accommodate the ligand scaffolds (Fig. 20).

Figure 21

More recent studies have confirmed that dual activation of PPAR γ and PPAR α subtypes would be beneficial for treating the type-2 diabetes [139]. In this connection KRP-297, a TZD derivative has been found to express the in vitro as well as in vivo affinity for both the PPAR α and PPAR γ subtypes [152]. In light of this, Desai and coworkers have investigated the PPAR α/γ dual agonistic activity of a series of TZD and oxazolidinedione derivatives (comp. **a**, Fig. 22, Table 14) for assessing their antidiabetic activity [153,154].

Figure 22

Table 14

Subsequently, Khanna et al have carried out the CoMFA and docking studies of these TZDs and oxazolidinediones in conjunction with their PPAR α / γ dual activity [155]. The common CoMFA model featuring the PPAR α and PPAR γ binding sites has been found to best explained the affinities of these ligands for the receptors (number of significant components=6; cross-validated r^2 (r^2_{cv})=0.782; non cross-validated r^2 (r^2_{ncv})=0.985). In this, the steric and electrostatic field contributions have been found to be 0.535 and 0.465 parts respectively (comp. **a**, Fig. 22 Table 14). Apart from this, for these compounds by making use of the protein sequences of PPAR γ and PPAR α molecular docking studies have also been carried out in FlexX. An earlier X-ray study of PPAR α and PPAR γ has suggested a common Y-shaped binding pocket for both the receptors with a difference in their amino acid content that is His323 in PPAR α being replaced by Tyr314 in PPAR γ [156]. In this background, it has been observed that in both the receptors, the compounds (ligands) have been found to assume a U-shape and bind to the enzyme through forming strong hydrogen bonds by involving the ligand's acidic fragment (thiazolidinedione moiety) and a set of residues (Tyr314, Tyr464, His440 and Ser280 in PPAR α , and His323, Tyr473, His449 and Ser289 in PPAR γ) in the active site. In light of this, the variations in the binding affinities of these compounds for the PPAR α / γ -receptors have been explained by using these differences. These studies exemplify the scope of the design of ligands from targeting 'a single receptor' to 'multiple receptors'.

3.2.4

Aldose Reductase Inhibitors

Some typical structural templates embedded with thiazolidine frame have been reported as potent inhibitors of *Aldose Reductase* (AR), an enzyme in polyol pathway responsible for the conversion of glucose to sorbitol. In this, the accumulation of sorbitol has been attributed to cause cataract, neuropathy and retinopathy in diabetic cases [157, 158]. The planar hydrophobic (aromatic) regions and propensity to charge transfer interactions have been identified as some known structural requirements of the AR inhibitors [159]. Considering these features together with eparestat (Fig. 23), a potent inhibitor of AR with

thiazolidine frame as part of its scaffold, Fresneau et al. have come up with new compounds, 2,4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acid (compound **a**, Fig. 23) and its 2-thioxo analogue (compound **b**, Fig. 23) as AR inhibitors [160].

Figure 23

In a pursuit to understand the binding modes of these inhibitors with AR, a molecular modeling study has been carried out with compounds (**a**) and (**b**) and these results have been compared with the crystal structure of the complex of AR and Zopolrestat, a known AR inhibitor (Fig. 23) [160,161]. This study has specifically identified three sites of interaction on the enzyme; site 1, an anionic pocket to accommodate a negative charge, such as a carboxylic group at the OH of Tyr48; site 2, a hydrophobic binding pocket with amino acids Trp111, Leu300 and Trp219 to accommodate aromatic moieties; and site 3 a hydrogen bonding site with SH of Cys298. This has led to suggest that a strong interaction at the identified sites would lead to better inhibitory activity for the compounds [160]. This study has illustrated an example of discovering novel compounds starting from the existing drugs and high active compounds.

3.2.5

Thromboxane A2 receptor antagonists

The emergence of thiazolidine derivatives as a structure class for the platelet aggregation inhibitory activity has its roots in a marine natural product, D-cysteinolic acid (**a**) [162,163]. The medicinal chemistry and modeling strategies have navigated D-cysteinolic acid (**a**) through various modifications to culminate into the thiazolidine analogues with different activity profiles (Fig. 24).

Figure 24

Among these compounds, D-cysteinolic acid (**a**) has exhibited mild platelet aggregation inhibitory activity and 2-(4-hydroxy-3-methoxyphenyl)-thiazolidine (**b**), a synthetically transformed compound of this natural product, has displayed an elevated activity, thus ushering thiazolidines into this pharmacological domain [162,163]. In this, the elevated activity may have resulted from the restriction in the spatial disposition of nitrogen and sulfur when compared to (**a**). Also this has clearly shown the necessity of mutual proximity of these heteroatoms in the molecular skeleton for the activity. From Fig.24, compounds **c** (3-Benzoyl-2-(4-hydroxy-3-methoxyphenyl)thiazolidine), **d** and **e** have been evaluated for their thromboxane A₂ (TxA₂) receptor antagonistic activity [164-166].

Pharmacologically thromboxane synthetase has a key role in the platelet aggregation and TxA₂ is its potent stimulator [167]. The antagonists of TxA₂ have important place in the treatment of various circulatory disorders [168]. Also these compounds are known to compete with the TxA₂ for the same receptor site. In this background some conformational mapping experiments between sulotroban and *o*-, *m*- and *p*-oxyacetic acid analogues of compound **e** (Fig. 24) have been carried out to explore the spatial relationship between TxA₂, sulotroban and the analogues of compound (**e**) (Fig. 24) [169]. Sulotroban (Fig. 24) is known to bind to TxA₂ receptor site in place of TxA₂. For this study, in conformity with the active conformation of TxA₂, the geometry of sulotroban has been considered in the form of a folded conformation [170]. This study has led Lacan et al to suggest that *m*-oxyacetic acid analogue of compound (**e**) map the sulotroban structure space best (Fig. 25) [169, 171]. This has signified the importance of the spatial disposition of the functional groups of these thiazolidines in deciding their TxA₂ antagonistic activity.

Figure 25

Some 2-disubstituted amino-4,5-dihydrothiazoles (compound **f**, Fig 24) have been reported to show in vivo antithrombotic activity. A QSAR study of these thiazoles (compound **f**, Fig 24, Table 15) with the physicochemical parameters namely Hammett's sigma (σ) constant, dipole moment (μ) and Swain and Lupton's polarity (F) constants of R₁ and R₂ substituent groups has resulted in the following equations [172].

Table 15

$$\text{Log (P/100-P)} = 0.301(0.076)F R_1 + 0.447(0.072)F R_2 - 0.485$$

$$n = 25, r = 0.855, \quad s = 0.097, \quad F = 29.88 \quad (25)$$

$$\text{Log (P/100-P)} = 0.254(0.079)F R_1 - 0.074(0.012) \mu R_2 - 0.449$$

$$n = 25, r = 0.850, \quad s = 0.099, \quad F = 28.56 \quad (26)$$

Based on these results it has been suggested that electronic factors - Hammett's sigma (σ) constant, dipole moment (μ) and Swain and Lupton's polarity (F) - are crucial for the antithrombotic activity of these compounds. Interestingly, in all the active compounds presented in Fig.24 the arrangement of substituents around thiazole skeleton is different from one another. This has further widened the scope of this skeleton in the exploration of potential platelet aggregation inhibitors and thromboxane A₂ receptor antagonist.

3.3

Anti-infective Agents

3.3.1

Anti-HIV Agents

Thiazolidines are also known to selectively intercept the biochemical processes of the pathogenic organisms such as bacteria, virus and fungi, in the host species.

Thiazolidines introduction into the HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) therapy is due to 1-Aryl-1*H*,3*H*-thiazolo[3,4-*a*]benzimidazole (TBZ) analogues (Fig. 26). Barreca et al have

modified the TBZ by opening its 'B' ring to explore the thiazolidines namely 2-(2,6-dihalo phenyl)-3-(substituted pyridin-2-yl)-thiazolidin-4-ones (Table 16) as potential anti-HIV-1 RT agents [173].

Figure 26

Table 16

In HIV type 1, all these compounds' activity is due to inhibition of a key viral enzyme, reverse transcriptase (RT), necessary for the catalytic transformation of single- stranded viral RNA into the double stranded linear DNA for incorporation into the host cell chromosomes [174]. The inhibitors of HIV-1 RT fall into two main classes. One is termed as nucleoside reverse transcriptase inhibitors (NRTIs). They mimic normal substrates of RT but lack the 3-'OH group required for the DNA chain elongation, and cause premature termination of the growing viral DNA strand [175]. The other is termed as non-nucleoside RT inhibitors (NNRTIs) and thiazolidine analogues belong to this class. They bind allostrically to a hydrophobic pocket close to the active site and achieve highly selective suppression of HIV-1 replication with little cytotoxicity to the host cells [176, 177]. Because of this considerable research efforts have been focused on the synthesis and structure-activity relationships of a large numbers of different compounds as NNRTIs [178]. The X-ray crystallographic studies of diverse NNRTIs/RT complexes have indicated that the NNRTIs, irrespective of their structure class, uniformly assume a "butterfly-like" like shape in the receptor (Fig 27)[179].

Figure 27

Barreca et al's modeling studies with 2-(2,6-dihalo phenyl)-3-(substituted pyridin-2-yl)-thiazolidin-4-ones (Fig. 26, Table 16) [173] in GRID and AutoDock [180] programs in conjunction with nevirapine (Fig. 26) have suggested that (a) the binding mode of these thiazolidine analogues is similar to that of TBZ and other

NNRTIs [173] and (b) the aliphatic and aromatic binding regions of nevirapine match with the 2,3-diaryl moieties of thiazolidin-4-ones scaffold.

The QSAR of these compounds has been analyzed in CP-MLR [51] procedure with physicochemical substituent constants [41] and several indicator parameters signifying their sub-structural features [181]. In this, the HIV-1 RT inhibitory activity of the compounds listed in Table 16 have been found to be correlated with the CLOGP, Swain and Lupton's resonance constant of 4'' position substituent ($R_{4''}$) and some indicator parameters as shown.

$$-\log EC_{50} = 0.415(0.135)CLOGP - 1.414(0.136)I_{4''} + 5.377$$

$$n = 23, r = 0.921, \quad Q^2 = 0.792, \quad s = 0.310, \quad F = 55.83 \quad (27)$$

$$-\log EC_{50} = 0.404(0.145)I_{2,3} - 1.327(0.141)I_{4''} + 6.668$$

$$n = 23, r = 0.916, \quad Q^2 = 0.787, \quad s = 0.319, \quad F = 52.04 \quad (28)$$

$$-\log EC_{50} = 0.439(0.141)CLOGP + 9.141(0.925)R_{4''} + 5.280$$

$$n = 23, r = 0.914, \quad Q^2 = 0.775, \quad s = 0.323, \quad F = 50.67 \quad (29)$$

In these equations indicator variable $I_{4''}$ has been defined for the 4''-substituent of 3-(pyridin-2-yl) moiety (zero for hydrogen and one otherwise) of thiazolidinones (Fig. 26). Also, in these compounds the HIV-1 RT inhibitory activity has been linked to their ability to take a “butterfly-like” like shape in the receptor.

Collectively the substituents of 2- and 3-aryl moieties of these compounds promote this molecular shape. In this connection, the indicator parameter $I_{2,3}$ has been introduced to address the collective steric features of the 2- and 3-aryl moieties of these compounds. In this, $I_{2,3}$ has been defined to take a value of ‘one’ if any one substituent at 2'- or 6'- of 2-phenyl moiety or at 3''- or 5''- positions of 3-(pyridin-2yl) moiety is larger than hydrogen and ‘zero’ otherwise. These equations while favoring for hydrophobic compounds, have clearly suggested that an unsubstituted 4''-position or a 4''-position substituent with positive resonance

contribution would be preferred for the HIV-1 RT inhibitory activity. The positive regression coefficient of $I_{2,3}$ has suggested the preference for substitution at one or more positions of 2', 6' of 2-phenyl and / or 3'', 5'' positions of 3-(pyridin-2-yl) moiety, hence favored the “butterfly-like” or an out of plane arrangement for the 2- and 3-aryl moieties. In these compounds a dual role has been assigned to the 3'', 5''-position substituents of 3-(pyridin-2-yl) moiety (Fig. 26) in terms of providing driving force to move the 3-pyridyl moiety to an out of plane arrangement with respect to the thiazolidinone nucleus and to fulfill hydrophobic and steric requirements at the receptor sites. The following regression equations have been derived to explain the HIV-1 RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(substituted phenyl)-thiazolidin-4-ones (Fig. 26, Table 17) alone (Eq. 30) and in combination with 2-(2,6-Dihalophenyl)-3-(substituted pyridin-2-yl)-thiazolidin-4-ones (Fig. 26 Table 16) (Eqs. 31 and 32) [181].

Table 17

$$-\log EC_{50} = 0.454(0.100) \pi_{(2'+6')} + 0.168(0.060) MR_{3''} - 0.014(0.005) (MR_{3''})^2 - 0.948(0.192) F_{3''} - 0.942(0.212) R_{(3''+5'')} + 5.655$$

$$n = 28, r = 0.867, \quad Q^2 = 0.620, \quad s = 0.247, \quad F = 13.38 \quad (30)$$

$$-\log EC_{50} = 0.356(0.080) CLOGP - 0.732 (0.259) R_{(3''+5'')} - 1.306(0.145) I_{4''} + 0.866(0.116) I_{2''} + 4.615$$

$$n = 51, r = 0.861, Q^2 = 0.695, \quad s = 0.319, \quad F = 33.12 \quad (31)$$

$$-\log EC_{50} = 0.363(0.081) CLOGP - 0.738(0.264) R_{(3''+5'')} + 8.424(0.960) R_{4''} + 0.883(0.118) I_{2''} + 4.585$$

$$n = 51, r = 0.856, \quad Q^2 = 0.684, \quad s = 0.325, \quad F = 31.69 \quad (32)$$

All these regression equations have suggested for the hydrophobic compounds for better inhibitory activity. Moreover, they have displayed the influence of polar/ inductive effects of the 3''- and 5''-position substituents on the activity. The

positive regression coefficient of I_2'' ('one' for 3-(pyridine-2-yl) and 'zero' for 3-phenyl) in equations 31 and 32 has suggested the advantage of 3-pyridyls over 3-phenyls for better inhibition of HIV-1 RT. A better blend of polarity, electronic and hydrophobic features in 3-pyridyls, compared to the corresponding phenyl analogue, has been attributed as one reason for these compounds' improved activity. Furthermore, in the PLS analysis of the total compounds of Tables 16 and 17, the descriptor I_2'' has emerged as the single largest contributing descriptor and thereby suggested the importance of 3-(pyridine-2-yl) moiety when compared to 3-phenyl moiety in HIV-1 RT inhibition. This has further suggested that the varying centers of this molecule have almost uniform influence on the activity [181].

In addition to the physicochemical domain, the topological features of selected HIV-1 RT inhibitors, 2-(2,6-dihalophenyl)-3-(substituted pyridin-2-yl)-thiazolidin-4-ones (Fig. 26, Table 16), have been analyzed [182] with the empirical, constitutional and graph theoretical descriptors from the DRAGON software [47]. This study has resulted in the identification of several influential descriptors to model the inhibitory activity and the equations showed below represent some models stemmed out from these descriptors.

$$-\text{LogEC}_{50} = -1.874(0.228) \text{AECC} - 300.003(30.650) \text{PW3} + 126.245$$

$$n = 24, r = 0.941, Q^2 = 0.855, s = 0.308, F = 80.89 \quad (33)$$

$$-\text{LogEC}_{50} = -263.490(24.496) \text{JGI4} + 8.236(0.923) \text{GGI7} + 21.831$$

$$n = 24, r = 0.944, Q^2 = 0.859, s = 0.301, F = 85.39 \quad (34)$$

$$-\text{LogEC}_{50} = 4.462(1.314) \text{MATS3v} - 1.037(0.103) \text{GATS8e} + 9.191$$

$$n = 24, r = 0.931, Q^2 = 0.824, s = 0.331, F = 68.59 \quad (35)$$

Equation 33 with AECC (the average eccentricity of the topological graph) and PW3 (Randic's molecular shape descriptor representing path/walk-3 ratio) has

represented a model from the simple topological descriptors, Eq. 34 with JGI4 (mean topological charge index of order 4) and GGI7 (topological charge index of order 7) has represented a model from the Galvez topological charge descriptors and Eq. 35 with MATS3v (Moran autocorrelation lag three weighed by atomic volumes) and GATS8e (Geary autocorrelation lag eight weighed by electronegativity) has represented a model from the 2D autocorrelation descriptors of the compounds. These equations have prompted to suggest that less extended or compact saturated structural templates would be better for the activity. Also, the participation of Galvez topological charge descriptors have indicated the importance of fourth and seventh eigenvalues of the polynomial of corrected adjacency matrix of the compounds' charge indices. The 2D autocorrelation descriptors have suggested the role of three and eight centered structural fragments of the compounds in the activity information. In terms of predictivity these equations have fared better than those involving physicochemical descriptors alone [182]. However, the topological models are more complex in nature when compared to physicochemical descriptors.

Roy and Leonard [183] have also presented QSAR models for the HIV-1 RT inhibitory activity of the thiazolidinones listed in Table 16, 17 along with some more similar analogues (Table 18) [184-187] using the hydrophobicity and molar refractivity, quantum chemical and topological and indicator parameters as descriptors. In this, the 3-pyridyls/ phenyls (Tables 16 and 17) and 3-(pyrimidin-2-yls) (Table 18) [186] have become part of the dataset. Additionally, four compounds with thiazolidin-4-thione nucleus have been included in the dataset. In Fujita-Ban [188] and mixed (Hansch and Fujita-Ban) approaches seven to seventeen descriptor models have been discovered for the cytopathicity effect (EC_{50}) and cytotoxic effect (CC_{50}) of the compounds. Following equations show the minimum descriptor models for the each activity from this study.

Table 18

$$-\log EC_{50} = 0.307(0.090)S_{\text{ssssC}} - 0.079(0.056)S_{\text{aasC}} + 0.837(0.291)\pi_3 - 1.363(0.355)E_6 + 2.729(1.074)E_{10} - 1.293(0.389)E_{18} + 6.663(4.395)D_1 -$$

$$1.339(0.732)I_{N_Z} - 0.490(0.203)N_{Me_RR1} - 0.501(0.508)I_{MeO_R3} - 1.847(0.708)I_{Me_R4} - 1.171(0.700)I_{Me_R6} - 2.103(0.435)I_{Me_R7} - 19.634(13.581)$$

$$n = 66, r = 0.911, \quad Q^2 = 0.504, \quad s = 0.334, \quad F = 19.60 \quad (36)$$

$$- \log CC_{50} = 0.051(0.048)S_{ssssC} - 0.035(0.028)S_{ssO} + 0.066(0.044)S_{sBr} + 0.788(0.676)\pi_{2'+6'} - 0.360(0.379)\pi_{2'+6'}^2 + 0.320(0.339)I_{N-W} - 0.253(0.114)I_{N-X} - 0.332(0.126)N_{Me-2'6'} - 0.362(0.339)I_{Cl-R4'} + 1.144$$

$$n = 83, r = 0.809, \quad Q^2 = 0.544, \quad s = 0.230, \quad F = 13.6 \quad (37)$$

In terms of the common structural components, Roy and Leonard's [183] observations have been in good agreement with the previous QSAR and modeling studies [181,182]. Additionally, they have suggested that thiazolidin-4-one nucleus is a preferred one when compared to thiazolidin-4-thione for the activity. Also, it has been noted that a methyl group at 5- and 3'-positions is detrimental to the activity, and both the 3-(pyridin-2-yl) and 3-(pyrimidin-2-yl) moieties as preferred ones for the HIV-1 RT inhibitory activity.

In a follow-up of our modeling studies on thiazolidine based HIV-1 RT inhibitors, we have synthesized some thiazolidin-4-ones, metathiazanones for this activity. The QSAR studies of these compounds with physicochemical and quantum chemical descriptors have highlighted the importance of PMIZ (moment of inertia Z-component), $\log P_{(o/w)}$ and MNDO_dipole in the HIV-1 RT inhibitory activity (comp. **a** and **b** Fig. 28, Table 19; comp. **c** Fig. 28, Table 20) [189, 190]. In these models, Eq.38 has been derived for thiazolidin-4-ones, metathiazanones (Table 19) and Eq.39 has been derived for thiazolidin-4-ones with furfuryl moiety in place pyridyl at N3 (Table 20).

Figure 28

Table 19

Table 20

$$-\log EC_{50} = -0.0018(0.0003) \text{ PMIZ} + 10.702$$

$$n = 5, r = 0.950, Q^2 = 0.573, s = 0.297, F = 27.91 \quad (38)$$

$$-\log EC_{50} = 1.479(0.206) \log P_{(o/w)} + 0.649(0.114) \text{ MNDO_dipole} - 1.191$$

$$n = 15, r = 0.920, Q^2 = 0.742, s = 0.501, F = 33.60 \quad (39)$$

In this study thiazolidin-4-ones have been found to retain the activity even with the introduction of furfuryl moiety in place pyridyl at N3. This has expanded the nature and scope of chemical space around the thiazolidin-4-one nucleus (comp. **c**, Fig. 28, Table 20) [190].

3.3.2

Antifungals Agents

The antifungal activity of azoles, emergence of opportunistic fungal infections due to AIDS and economic considerations of agro and food industry has generated considerable momentum to discover and explore other prototypes for the chemotherapy of fungal diseases. In this context, some thiazolidines, thiazoles and thiadiazoles have been found to display antifungal activity against different human and plant pathogenic fungi.

In an exploratory study, some 2,3,4-substituted thiazolidines (Fig. 29; Table 21) have been discovered to show a broad spectrum in vitro antifungal activity against human pathogenic fungi namely *Candida albicans* (CA), *Cryptococcus neoformans* (CN), *Tricophyton mentagrophyte* (TM) and *Aspergillus fumigatus* (AF) [191]. The antifungal activities of these compounds have been analyzed in 2D- and 3D-QSAR studies to map the activity and to identify the common pharmacophore for the design of broad spectrum antifungals. Apex-3D module of InsightII [69] has been put to use in the 3D-QSAR analysis. The following 3D-QSAR equations have emerged from a molecular superimposition patterns based

on three-biophoric sites of these compounds for their activity against the fungal strains CN, TM and AF, respectively (Fig 30).

Figure 29

Table 21

$$-\log\text{MIC}(\text{CN}) = 0.013(0.002)\text{TREF} - 0.427(0.079)\text{IR}_m + 4.475(1.593)\pi_a(\text{ss1}) + 0.099(0.041)\text{REF}_a(\text{ss2}) - 0.095(0.026)\text{REF}_a(\text{ss3}) - 0.102(0.037)\text{REF}_a(\text{ss4}) + 0.356(0.090)\text{I-Ring}(\text{ss5}) - 0.026$$

$$n = 50, r = 0.808, \quad s = 0.197, \quad F = 11.26 \quad (40)$$

$$-\log\text{MIC}(\text{TM}) = 0.005(0.001)\text{TREF} - 0.485(0.115)\pi_a(\text{ss1}) - 0.058(0.015)\text{REF}_a(\text{ss2}) - 0.027(0.012)\text{REF}_a(\text{ss3}) - 0.064(0.016)\text{REF}_a(\text{ss4}) + 0.080(0.027)\text{REF}_a(\text{ss5}) + 0.452$$

$$n = 53, r = 0.805, \quad s = 0.145, \quad F = 14.11 \quad (41)$$

$$-\log\text{MIC}(\text{AF}) = -0.419(0.135)\text{HA}(\text{ss1}) - 0.261(0.138)\text{HA}(\text{ss2}) - 0.362(0.090)\text{HA}(\text{ss3}) + 0.420(0.141)\text{HD}(\text{ss4}) + 2.594(0.522)\pi_a(\text{ss5}) - 0.313(0.150)\pi_a(\text{ss6}) + 0.130(0.034)\text{REF}_a(\text{ss7}) + 1.086$$

$$n = 36, r = 0.841, \quad s = 0.119, \quad F = 9.63 \quad (42)$$

In development of these equations, for the 3D-molecular superimpositions, the carbonyl oxygen in the vicinity of C4, S1, N3, oxygen of t-butyloxycarbonyl or benzoyl group attached to N3 and / or C2-phenyl moiety of thiazolidines have provided the biophoric sites (Fig 30). The parameters of these equations represent global attributes of the compounds (global parameters - TREF, total refractivity; IR_m, the nature of the meta-substituent of C2-phenyl moiety) and / or conformational dependent attributes from molecular superimposition pattern

(secondary sites or ss; descriptors identified with suffix 'ss'). In 3D-QSAR studies, all the secondary sites are local to each equation. They are conformation sensitive and location specific in the 3D-structure space. In these equations π_a , REF_a , I-Ring, HA and HD addressed the hydrophobicity, refractivity, aromatic ring indicator, H-acceptor and H-donor properties, respectively, of atoms or groups (secondary sites) at the predefined locations in the 3D space of corresponding models (Fig. 30). These equations have led to suggest that AF is sensitive to the structural and conformational features of the compounds. Fig. 31 provides a composite 2D-representation of the biophoric and secondary sites pattern of the thiazolidines 3D-equations (Fig. 30; Eqs.40 to 42).

Figure 30

Figure 31

A fundamental difference between 3D- and a 2D-QSAR equation is the non-existence of conformational dependent secondary sites in the latter. Hence, a direct transposition of 3D- and 2D-models is not always possible but the global properties of the chemical structures, if relevant to the activity, may show their presence in both of them. Moreover, in a broader perspective, all 2D-QSAR parameters - physicochemical as well as structural - can be considered as one or other form of global descriptors. In the light of this, to bridge the 2D- and 3D-features the following 2D-QSAR equations have been derived for the antifungal activity of 2,3,4-substituted thiazolidines (Table 21).

$$-\log\text{MIC}(\text{CN}) = 0.011(0.003)\text{MRR}_2 + 0.751(0.162)\text{VwR}_1 - 0.335(0.061)\text{IR}_m + 0.706$$

$$n = 41, r = 0.800, \quad s = 0.187, \quad F = 21.86 \quad (43)$$

(excluded compounds: **12**, **13**, **19**, **43**, **44**, **54**, **56**, **59** and **60**)

$$-\log\text{MIC}(\text{TM}) = 0.005(0.0007)\text{TREF} + 0.217(0.098)\text{FR}_p + 0.280$$

$$n = 47, r = 0.734, \quad s = 0.113, \quad F = 25.74 \quad (44)$$

(excluded compounds: **15, 34, 38, 55, 58** and **63**)

$$-\log\text{MIC}(\text{AF}) = -0.039(0.009)\text{MRR}_2 + 0.002(0.0004)\text{MRR}_2^2 - 2.357(1.074)\text{FR}_p + 6.048(2.787)\text{FR}_p^2 - 0.620(0.300)\sigma\text{R}_p + 0.971$$

$$n = 30, r = 0.777, \quad s = 0.124, \quad F = 7.29 \quad (45)$$

(excluded compounds: **21, 29, 36, 55, 63** and **64**)

In deriving these equations several compounds have been excluded from the dataset. In 2D-QSAR, the descriptors TREF, IR_m, MRR₂, VwR₁, FR_p and σR_p have been found to be the parameters of choice to explain the antifungal activity of the compounds with TREF and IR_m as common variables for both 3D- and 2D-equations. With the identification of the 2D-parameters in the 3D-region, that is R₂ to the C4 region, R₁ to the N3 region and R_p to the C2-phenyl moiety, the 2D and 3D-studies have been integrated to diagnose the activity of the compounds.

The thiazolidines' (Table 21) activity against CA has been found to be distributed in a very narrow range. Also, no 3D-molecular/ conformational preferences of these compounds have been noticed in deciding this antifungal activity (Eqs. 46 and 47).

$$-\log\text{MIC}(\text{CA}) = 0.179 + 0.001(0.00001)\text{MW}$$

$$n = 48, r = 0.997, \quad s = 0.005, \quad F = 7689.85 \quad (46)$$

$$-\log\text{MIC}(\text{CA}) = 0.210 + 0.004(0.00001) \text{TREF}$$

$$n = 48, r = 0.976, \quad s = 0.015, \quad F = 934.85 \quad (47)$$

These equations have indicated a strong correlation between the CA inhibitory activity and global properties namely, molecular weight (MW) and total refractivity (TREF), of these compounds. This exploration has elucidated the

potential of the thiazolidines as antifungal agents. Some 1:1 adducts of triphenyltin chloride and 2,3-disubstituted thiazolidin-4-ones have been evaluated, in vitro, against the plant pathogenic fungus, Dutch elm, *Ceratocystis ulmi* [192]. However, attempts to obtain structure-activity correlations between the activity and the descriptors of triphenyltin chloride and thiazolidin-4-one adduct have been reported to be unsuccessful [192].

Zou et al [193] have explored the QSAR of the antifungal profile of 5-[1-aryl-1,4-dihydro-6-methylpyridazin-4-one-3-yl]-2-arylamino-1,3,4-thiadiazoles (Fig. 32, Table 22) in terms of the sum of the physicochemical properties of all the substituent groups namely, hydrophobic effects ($\sum\pi$), meta- and para- Hammett's sigma constants ($\sum\sigma$), steric effects ($\sum E_s$) and the inductive effects ($\sum F$).

Figure 32

Table 22

These compounds have been tested in vivo against wheat leaf rust, *Puccinia recondite*, at a fixed dose of 0.001M. The following equation has represented the best QSAR model for the antifungal activity ($D = \log[a/(100-a)] - \log Mw$; where, **a** is the percentage inhibition and Mw is the molecular weight of the tested compound) of these compounds.

$$D = 2.802(0.450)\sum\pi - 3.275(0.534)\sum\sigma + 0.995(0.214)\sum E_s - 0.936(0.21)\sum F - 2.844$$

$$n = 16, r = 0.902, \quad s = 0.281, \quad F = 11.96 \quad (48)$$

Based on this equation Zou et al have concluded that hydrophobic compounds with inductively electron donating ortho substituents would be favorable for the activity [193]. In continuation of this, Zou and co-workers have carried out CoMFA based 3D-QSAR analysis of these compounds together with 5-[1-aryl-1,4-dihydro-6-methylpyridazin-4-one-3-yl]-2-arylamino-1,3,4-oxadiazoles [194].

Here also the antifungal activity of these compounds has been found to be well explained by their steric and electrostatic properties. In addition to this, it has confirmed the bioisosterism between the 1,3,4-thiadiazole and 1,3,4-oxadiazole analogues in expressing the antifungal activity (Fig. 33)

Figure 33

3.3.3

Octopamine Agonists (OA)

Several scaffold closely related to thiazolidines have been reported to possess octopamine (OA) agonist/ antagonist activity mediated through the adenylate cyclase. The OA is associated with the altered levels of cyclic AMP in nerve tissue of insects, e.g., the migratory locust, *Locusta migratoria* L [195-199]. This has prompted the investigation of these heterocycles as safe and selective pesticides [200,201]. In this background Hirashima et al have investigated the QSAR of octopaminergic agonistic activity of 2-(arylimino)thiazolidine derivatives (Fig. 34, Table 23) [202] with different physicochemical parameters such as total hydrophobicity ($\Sigma\pi$), molar refraction (MR), electronic effect sigma meta constant (σ_m), steric (Es), Steric meta (Es^m), Swain and Lupton's polarity (\mathcal{F}) and resonance constants (\mathcal{R}). In these compounds the relative maximal efficacy of the compounds, $\log V_{\max}$ has been shown to be correlated with the parameters $\Sigma\pi$, σ_p and Es^m (Eq. 49) [203].

Figure 34

Table 23

$$\log V_{\max} = 0.784(0.055) + 0.261(0.055)\Sigma\pi + 0.173(0.095)\sigma_p + 0.266(0.050)Es^m$$

$$n = 41, r = 0.744, \quad s = 0.229, \quad F = 15.26 \quad (49)$$

Based on this model, it has been concluded that more hydrophobic compounds having *ortho* and *para* substituent with electron withdrawing property and a less bulky *meta*-position substituents would lead to better activity. In these compounds octopamine agonistic activity in terms of K_a , the concentration of the agonist necessary for half-maximal activation of adenylate cyclase, and its $\text{Log}V_{\text{max}}$ are mutually correlated. This has prompted to suggest that larger the V_{max} value, greater would be the activity of the compounds [202].

In 2-(substituted benzylamino)-2-thiazolines (Fig. 35, Table 24) [204,205] the octopamine agonist activity ($\text{log}V_{\text{max}}$) has been reported to be correlated with the parameters σ_m and E_s^m as shown [206].

Figure 35

Table 24

$$\text{Log } V_{\text{max}} = 0.663(0.125) \sigma_m + 0.118(0.036) E_s^m + 1.414$$

$$n = 17, r = 0.855, \quad s = 0.048, \quad F = 19.11 \quad (50)$$

In these compounds the *meta* substituent's electronic and steric effect have been found to be important for the OA agonistic activity. Similar to the compounds of Table 24, for 2-(substituted benzylamino)-2-thiazolines (Fig. 35, Table 24) also less bulky *meta*-substituents have been reported as favorable for the activity. The positive regression coefficient of σ_m has suggested for more electron-withdrawing substituents at this position. However, in these compounds, the K_a and V_{max} are negatively correlated. This has been attributed to the phenyl substituents of these compounds [206].

Thiazolidines and related compounds have also been indicated for their pheromone production inhibitory activity in female moths, *Helvicoverpra armigera*. Pheromone production is a chemical signaling pathway related to octopaminergic receptor in moths for controlling their reproductive behavior [207-212]. For a set of ten compounds (Fig. 36, Table 25) [213,214] Hirashima

and co-workers have identified the following 3D-QSAR model in GFA to explain their OA agonistic activity (K_i) (Eq. 51) [215].

Figure 36

Table 25

$$pK_i = -0.082 \text{ LowEne} - 14.819 \text{ SXZF} + 8.818 \text{ JX} + 0.004 (\text{MR} - 57.7808)^2 + 3.085$$

$$n = 10, r = 1.000, \quad F = 5681.367 \quad (51)$$

In this equation LowEne is the energy of the most stable conformation, SXZF is the fraction of area of molecular shadow in the XZ plane over area of enclosing rectangle, JX is a topological parameter from Balaban's shape indices and MR is the molecular refractivity. Hirashima and co-workers have interpreted this equation to suggest that compounds with positive JX, negative or smaller LowEne and SXZF would result in improved activity [215]. In continuation of this study they have analysed these compounds using molecular shape analysis (MSA), molecular field analysis (MFA) and receptor surface model (RSM) [216]. In MSA a significant equation for the activity of these compounds has been discovered with information content (IC), radius of gyration (RG) and common overlap steric volume (COVS) (Eq. 52). Models from MFA have involved the potentials of the 3D-grid points generated from the atomic coordinates of the contributing models. The MFA model identified for these compounds has laid emphasis on the proton probes corresponding to lattice points H+/372, H+/298 and methyl probe corresponding to lattice point CH3/164 (Eq. 53). The RSM analysis has highlighted the associated steric, physicochemical and electronic properties of the grid of hypothetical receptor site of the compounds. The RSM equation (Eq. 54) of these compounds has emerged from the electrostatic interaction energy (ELE) at grid points 137 (ELE/137) and 546 (ELE/546) and van der Waals interaction energy at point 780 (VDW/780).

$$pK_i = -0.960(IC)^2 - 6.579RG - 0.055(152.765 - COSV)^2 + 39.1401$$

$$n=10, r=0.992, \quad F=119.50 \quad (52)$$

$$pK_i = -0.003(H+/372)^2 + 0.063(H+/298) + 0.025CH_3/164 + 7.209$$

$$n=10, r=0.997, \quad F=407.92 \quad (53)$$

$$pK_i = 2.763ELE/137 - 1.529 \times (ELE/546)^2 - 0.061VDW/780 + 8.214$$

$$n=10, r=0.994 \quad F=184.36 \quad (54)$$

These equations have highlighted the steric, physicochemical, and electronic requirements at the specified grid locations of the compounds and the pseudo receptor [216].

3.3.4

Trehalase Inhibitors

Also, Thiazolidine derivatives have been reported to control insect's energy metabolism through the inhibition of trehalase, an enzyme involved in the energy functions, especially in the insect-flight [217, 218]. The affinity of trehazolin (**a**) for this enzyme has motivated to explore 2-aryliminothiazolidine/ oxazolidine derivatives (comp. **b**, Fig 37, Table 26) as its inhibitors [219].

Figure 37

Table 26

The QSAR of the trehalase inhibitory activity (pIC₅₀) of these compounds has been investigated with dipole moment (D), lipophilicity (V₁/V₂, where V₁ and V₂

correspond to nonpolar surface area and polar surface area (\AA^2) of water solvation shell respectively) and length (d_2).

$$\text{pIC}_{50} = 0.376(0.124)D + 3.174 (0.624) d_2 - 2.071(0.529) V_1/V_2 - 5.109$$

$$n = 10, r = 0.830, \quad s = 0.335, \quad F = 9.79 \quad (\text{Eq.55})$$

Based on this model, it has been concluded that polar compounds with higher d_2 values would be better for the activity. Moreover, it has suggested that hydrophilic compounds would lead to the better inhibitory activity.

4

Concluding Remarks

The present review has addressed the twin issues namely, applications of QSAR in rational drug design and more importantly highlighted the potential of thiazolidine ring system as a biologically privileged scaffold. Over the years there has been a substantial progress in QSAR methodologies from the classical to high dimensional modeling studies leading to more realistic prediction physicochemical properties as well as the biological activities of compounds under investigation. Through the examples cited in this review we have tried to emphasize that by rational design, biological activity inherent to the chemical entities can be accentuated culminating in therapeutically useful molecules. The studies on Neuropeptide Y5 receptor (NPY5R) antagonists as antiobesity agents has clearly illustrated how the modeling studies can be focused in the design of novel and high active compounds for the identified target. In this case, highly active NPY5R antagonists with thiazole scaffold have been designed using modeling studies starting from totally unrelated chemical entities [130,131]. QSAR study of the antihistaminic (H_1) activity of substituted thiazoles and benzthiazole derivatives [111,112] using the logP and normal and reversed phase thin layer chromatographic (TLC) parameters generated through impregnating the TLC plates with the amino acids of the receptor domain provided an intuition

about the nature and requirements of receptor domain vis-à-vis the compounds under investigation. Also, it has provided handle to deal the much larger problems of receptor domain with simple yet reliable tools. This study has opened up a novel way of generating the receptor directed interaction information in terms of amino acids of the active site. One can also adapt this kind of procedure for the study of other receptors. Another interesting example discussed in this review involves a simple classification of antiulcer activity of 4-substituted-2-guanidino thiazoles with topological indices namely Wiener's and molecular connectivity indices [117]. These approaches are very handy and quick for the screening of large databases. The QSAR and modeling results of thiazolidin-4-ones as HIV-1 RT inhibitors from different groups have shown consistency from different perspectives and provided a scope to expand the substitution around the thiazolidinone moiety by the introduction of furfuryl in place pyridyl at N3 [173,181-183,189,190]. Through these and other examples we have tried to highlight the prospects of this heterocyclic system as well as QSAR and modeling studies in the lead identification, development and optimization in drug discovery program.

Acknowledgements. Two of the authors (VRS and MKG) gratefully acknowledge CSIR, New Delhi India for financial support in the form of Senior Research Fellowship. CDRI communication no. 6894.

References

1. Abraham DJ (2003) *Burgers Medicinal Chemistry and Drug Discovery*, 6th edn. Vol John Wiley & Sons, New Jersey
2. Frühbeis H, Klein R, Wallmeier H (1987) *Angew Chem Int Ed* 26:403
3. Livingstone D (1995) *Data Analysis for Chemists: Applications to QSAR and Chemical Product Design*, Oxford University Press
4. Negwer M (1994) *Organic-Chemical Drugs and Their Synonyms*, 7th edn. Akademie Verlag, VCH Publishers New York
5. Koch P, Perrotti E (1974) *Tetrahedron Lett* 15:2899
6. Cook AH, Heilbron I (1949) In: *The chemistry of penicillin*. Princeton University Press, Chap 25, p 921
7. Metzger JV (1984) *Comprehensive heterocyclic chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic compounds*. In: Katrizky AR, Rees CW, Potts KT (eds) *Thiazoles and their benzo derivatives*. Pergamon Press, p 235
8. Pesek J, Frost J (1975) *Tetrahedron* 31:907
9. Brich A, Harris S (1930) *Biochem J* 24:1080
10. Schubert J (1935) *Biochem J* 111:671
11. Kallen RG (1971) *J Am Chem Soc* 93:6236
12. Wystouch A, Lisowski M, Pedyczak A, Siemion IZ (1992) *Tetrahedron Assym* 3:1401
13. Patek M, Darke B, Lebel M (1995) *Tetrahedron Lett* 36:2227
14. Pesek JJ, Frost JH (1975) *Tetrahedron* 31:907
15. Dains FB, Krober OA (1939) *J Am Chem Soc* 61:1830
16. Damico JJ, Harman MH (1955) *J Am Chem Soc* 77:476
17. Bon V, Tisler M (1962) *J Org Chem* 27:2878
18. Rao RP (1961) *J Indian Chem Soc* 38:784
19. Bhargava PN, Chaurasia MR (1969) *J Pharm Sci* 58:896
20. Chaubey VN, Singh H (1970) *Bull Chem Soc Jpn* 43:2233
21. Wilson FJ, Burns R (1922) *J Chem Soc* 121:870
22. Bougault J, Cattelain E, Chabrier P, Quevauviller A (1949) *Bull Soc Chim Fr* 16:433
23. Surrey AR, Cutler RA (1954) *J Am Chem Soc* 76:578
24. Srivastava SK, Srivastava SL, Srivastava SD (2000) *J Indian Chem Soc* 77:104
25. Shrama RC, Kumar D (2000) *J Indian Chem Soc* 77:492
26. Baraldi PG, Simoni D, Moroder F, Manfredini S, Mucchi L, Vecchia FD (1982) *J Heterocycl Chem* 19:557
27. Srivastava T, Haq W, Katti SB (2002) *Tetrahedron* 58:7619
28. Rawal RK, Srivastava T, Haq W, Katti SB (2004) *J Chem Res* 368
29. Holmes C, Chinn JP, Look GC, Gordon EM, Gallop MA (1995) *J Org Chem* 60:7328
30. Popp FD, Rajopadhye M (1987) *J Heterocycl Chem* 24:261
31. Brown FC, Jones RS, Kent M (1963) *Can J Chem* 41:817
32. Liu H, Li Z, Anthonsen T (2000) *Molecules* 5:1055
33. Kato T, Ozaki T, Tamura K, Suzuki Y, Akima M and Ohi N (1999) *J Med Chem* 42:3134
34. Troutman HD, Long LM (1948) *J Am Chem Soc* 70:3436

35. Surrey AR (1948) *J Am Chem Soc* 70:4262
36. Omar MT, El-Khamry AE, Sherif FA (1981) *J Heterocycl Chem* 18:633
37. Brown FC (1961) *Chem Rev* 61:463
38. Danila G (1978) *Rev Chim (Bucharest)* 29:820 *Chem Abstr* (1979) 90:72086p
39. Danila G (1978) *Rev Chim (Bucharest)* 29:1152 *Chem Abstr* (1979) 90:152037p
40. Singh SP, Parmar SS, Raman K, Stenberg VI (1981) *Chem Rev* 81:175
41. Hansch C, Leo A (1979) *Substituent Constants for Correlation Analysis in Chemistry and Biology*. Wiley-Interscience, New York
42. Stewart JJP (2004) *J Mol Model* 10:155 and earlier references
43. CS Chem3D Ultra[®] Cambridge Soft Corporation, Cambridge, USA
44. Katritzky AR, Lobnov V, Karelson M (1994) *CODESSA* (Comprehensive Descriptors for Structural and Statistical Analysis) University of Florida, Gainesville, FL, <http://www.codessa-pro.com>
45. Katritzky AR, Perumal S, Petrukhin R, Kleinpeter E (2001) *J Chem Inf Comput Sci* 41:569
46. Liu SS, Yin CS, Li ZL, Cai SX (2001) *J Chem Inf Comput Sci* 41:321
47. DRAGON software version 3.0 (2003) Todeschini R, Consonni V, Mauri A, Pavan M, Milano, Italy. <http://disat.unimib.it/chm/Dragon.htm>
48. Wold S, Ruhe A, Wold H, Dunn WJ (1984) *J Sci Stat Comput* 5:135
49. Rogers D, Hopfinger AJ (1994) *J Chem Inf Comput Sci* 34:854
50. Cerius² Version 4.8 (2002) Accelrys Inc, San Diego, USA <http://www.accelrys.com/cerius2>
51. Prabhakar YS (2003) *QSAR Comb Sci* 22:583
52. Liu SS, Liu HL, Yin CS, Wang LS (2003) *J Chem Inf Comput Sci* 43:964
53. Gasteiger J, Zupan J (1993) *Angew Chem Intl Ed* 32:503
54. Manallack DT, Ellis DD, Livingstone DJ (1994) *J Med Chem* 37:3758
55. Kövesdi I, Dominguez-Rodriguez MF, Ôrfi L, NÁray-Szabó G, Varró A, Gy Papp J, Mátyus P (1999) *Med Res Rev* 19:249
56. Cramer RD, Patterson DE, Bunce JD (1998) *J Am Chem Soc* 110:5959
57. Klebe G, Abraham U, Meitzner T (1994) *J Med Chem* 37:4130
58. Hopfinger A J (1980) *J Am Chem Soc* 102:7196
59. Tokarski JS, Hopfinger AJ (1994) *J Med Chem* 37:3639
60. Hopfinger AJ, Tokarsi JS (1997) In: Charifson PS (ed) *Practical applications of computer-aided drug design*. Marcel Dekker Inc, New York, p 105
61. Hahn M (1995) *J Med Chem* 38:2080
62. Hahn M and Rogers D (1995) *J Med Chem* 38:2091
63. Golender VE, Vorpogel ER (1993) *Computer Assisted-Pharmacophore Identification. 3D-QSAR in Drug Design: Theory, Methods and Application*, Kubinyi, H. ESCOM Science Publishers: Netherlands, 137
64. *Rational Drug Design Software Catalyst*, Accelrys, San Diego, CA. <http://www.accelrys.com/catalyst>
65. Cox B, Denyer JC, Binnie A (2000) *Prog Med Chem* 37:83
66. Walters WP, Stahl MT, Murcko MA (1998) *Drug Discovery Today* 3:160
67. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1988) *J Comput Chem* 9:1639
68. AutoDock: Automated docking of flexible ligands to macromolecules <http://www.scripps.edu/mb/olson/doc/autodock>
69. Insight II, version 2.3.0, Biosym Technologies Inc, 9685, Scranton Road, San Diego, CA, USA, 1993
70. SYBYL 6.9 Tripos Inc., 1699 S. Hanley Rd., St. Louis, MO 63144 USA.

71. MOE: The Molecular Operating Environment, Chemical Computing Group Inc. Quebec, Canada.
<http://www.chemcomp.com>
72. Klose N, Niedbolla K, Schwazrtz K, Bottcher I (1983) Arch Pharm 1983:316
73. Satsangi RK, Zaidi SM, Misra VS (1983) Pharmazie 38:341
74. Pignatello R, Mazzone S, Panico AM, Mazzone G, Penissi G, Castano R, Matera M, Blandino G (1991) Eur J Med Chem 26:929
75. Hadjipavlou-Litina D, Geronikaki A, Sotiropoulou E (1993) Res Commun Chem Pathol Pharmacol 79:355
76. Geronikaki A, Hadjipavlou-Litina D (1993) Pharmazie 48:948
77. Garg R, Kurup A, Mekapati SB, Hansch C (2003) Chem Rev 103:703
78. Fleischmann R, Iqbal I, Slobodin G (2002) Expert Opin Pharmacother 10:1501
79. Naito Y, Goto T, Akahoshi F, Ono S, Yoshitomi H, Okada T, Sugiyama N, Abe S, Hanada S, Hirata M, Watanabe M, Fukaya C, Yokoyama K, Fujita T (1991) Chem Pharm Bull 39:2323
80. Naito Y, Yamaura Y, Inoue Y, Fukaya C, Yokoyama K, Nakagawa Y, Fujita T (1992) Eur J Med Chem 27:645
81. Verloop A, Hoogenstraaten W, Tipkar J (1976) In Drug Design, Ariens EJ (Ed) Academic Press NY, Vol. VII 165-207
82. Liu SS, Cui SH, Shi YY, Wang LS (2002) Internet Electron J Mol Des 1:610
83. Liu SS, Yin CS, Shi YY, Cai SX, Li ZL (2001) Chin J Chem 19:751
84. Liu SS, Liu LH, Shi YY, Wang LS (2002) Internet Electron J Mol Des 1:310
<http://www.biochempress.com>
85. Vigorita MG, Ottanà R, Monforte F, Maccari R, Monforte MT, Trovato A, Taviano MF, Miceli N, De Luca G, Alcaro S, Ortuso F (2003) Bioorg Med Chem 11:999
86. Pettipher ER, Higgs GA, Henderson B (1986) Proc Natl Acad Sci USA 83:874
87. Panico AM, Geronikaki A, Mgonzo R, Cardile V, Gentile B, Doytchinova I (2003) Bioorg Med Chem 11:2983
88. McInnes IB, Leung PB, Field M, Huang FP, Sturrock RD, Kinnim J (1996) J Exp Med 184:1519
89. Misra R, Stephan S, Chander CL (1999) Inflamm Res 48:S119
90. De Nanteuil G, Portevin B, Benoist A (2001) Il Farmaco 56:107
91. Litina DH, Geronikaki A, Mgonzo R, Doytchinova I (1999) Drug Develop Res 48:53
92. Ellis GA, Blake DR (1993) Ann Rheum Dis 52:241
93. van Muijlwijk-Koezen JE, Timmerman H, Vollinga RC, von Drabbe F, Kunzel J, de Groote M, Visser S, IJzerman AP (2001) J Med Chem 44:739
94. van Tilburg EW, van der Klein PAM, de Groote M, Beukers MW, IJzerman, AP (2001) Bioorg Med Chem Lett 11:2017
95. Jung KY, Kim SK, Gao ZG, Gross AS, Melman N, Jacobson KA, Kim YC (2004) Bioorg Med Chem 12:613
96. Fan M, Qin W, Mustafa SJ (2003) Am J Physiol Lung Cell Mol Physiol 284:L1012
97. Ezeamuzie CI (2001) Biochem Pharmacol 61:1551
98. Avila MY, Stone RA, Civan MM (2002) Invest Ophthalmol Vis Sci 43:3021
99. Mubagwa K, Flameng W (2001) Cardiovasc Res 52:25
100. Liang BT, Jacobson KA (1998) Proc Natl Acad Sci USA 95:6995
101. Tracey WR, Magee W, Masamune H, Kennedy SP, Knight DR, Buchholz RA, Hill R (1997) J Cardiovasc Res 33:410
102. von Lubitz DKJE (1999) Eur J Pharmacol 371:85
103. Bhattacharya P, Leonard JT, Roy K (2005) Bioorg Med Chem 13:1159

104. Bhattacharya P, Leonard JT, Roy K (2005) *J Mol Model* 11:516
105. Borghini A, Pietra D, Domenichellia P, Bianucci AM (2005) *Bioorg Med Chem* 13:5330
106. Naruto S, Motoc I, Marshall GR (1985) *Eur J Med Chem* 20:529
107. Borea PA, Bertolasi V, Gilli G (1986) *Arzneim. Forsch.* 36:895
108. Diurno MV, Mazzoni O, Piscopo E, Caliganao A, Giordano F, Bolognese A (1992) *J Med Chem* 35:2910
109. Singh P, Ojha TN, Shrama RC, Tiwari S (1994) *Indian J Pharm Sci* 57:162
110. Agrawal VK, Sachan S, Khadikar PV (2000) *Acta Pharma* 50:281
111. Brzezinska E, Koska G, Walczynski K (2003) *J Chromatogr A* 1007:145
112. Brzezinska E, Koska G, Klimczak A (2003) *J Chromatogr A* 1007:157
113. Walczynski K, Timmerman H, Zuiderveld OP, Zhang MQ, Glinka R (1999) *Il Farmaco* 54:533
114. Walczynski K, Guryrn R, Zuiderveld OP, Zhang MQ, Timmerman H (1999) *Il Farmaco* 54:684
115. Walczynski K, Guryrn R, Zuiderveld OP, Zhang MQ and Timmerman H (2000) *Il Farmaco* 55:569
116. La Mattina JL, McCarthy PA, Reiter LA, Holt WF Yeh LA (1990) *J Med Chem*, 39, 543
117. Goel A, Madan A K (1995) *J Chem Inf Comput Sci* 35:504
118. Wiener H (1947) *J Am Chem Soc* 69, 2636
119. Randić M (1975) *J Am Chem Soc* 97, 6609
120. Borges EG, Takahata Y (2002) *J Mol Struct (Theochem)* 580:263
121. Mizoule J, Meldrum B, Martine M, Croucher M, Ollat C, Uzan A, Legvand JJ, Gueremy C, LeFur G (1995) *Neuropharmacology* 24:767
122. Benoit E, Escande D (1991) *Pflugers Arch* 419:603
123. Hays SJ, Rice MJ, Ortwine DF, Johnson G, Schwarz RD, Boyd DK Copeland LF, Vartanian MG, Boxer PA (1994) *J Pharma Sci* 83: 1425
124. Mathvink RJ, Barritta AM, Candelore MR, Cascieri MA, Deng L, Tota L, Strader CD, Wyvratt MJ, Fisher MH, Weber AE (1999) *Bioorg Med Chem Lett* 9:1869
125. Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF, Deng LJr, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Tota L, Wyvratt M J, Fisher MH, Weber AE (2000) *Bioorg Med Chem Lett* 10:1971
126. Nisoli E, Tonello C, Carruba MO (2003) *Curr Med Chem Central Nervous Syst Agents* 3: 257
127. Naylor EM, Parmee ER, Colandrea VJ, Perkins L, Brockunier L, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Strader CD, Tota L, Wang PR, Wyvratt MJ, Fisher MH, Weber AE (1999) *Bioorg Med Chem Lett* 9:755
128. Shih TL, Candelore MR, Cascieri MA, Chiu SHL, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Strader CD, Tota L, Wyvratt MJ, Fisher MH, Weber AE (1999) *Bioorg Med Chem Lett* 9:1251
129. Hanumantharao P, Sambasivarao SV, Soni LK, Gupta AK, Kaskhedikar SG (2005) *Bioorg Med Chem* 15:3167
130. Guba W, Neidhart W, Nettekoven M (2005) *Bioorg Med Chem Lett* 15: 1599
131. Nettekoven M, Guba W, Neidhart W, Mattei P, Pflieger P, Roche O, Taylor S (2005) *Bioorg Med Chem Lett* 15:3446
132. Criscione L, Rigollier P, Batzl-Hartmann C, Rueger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, Levens N (1998) *J Clin Invest* 102:2136
133. Fukami T, Okamoto O, Fukuroda T, Kanatani A, Ihara M (1998) *PCT Int Appl WO 9840356* (Banyu Pharmaceutical Co Ltd, Japan) 78

134. Norman MH, Chen N, Han N, Liu L, Hurt CR, Fotsch CH, Jenkins TJ, Moreno OA (1999) PCT Int Appl WO9940091 (Amgen Inc, USA) 469
135. Breu V, Dautzenberg F, Guerry P, Nettekoven MH, Pieger P (2002) PCT Int Appl WO2002020488 (F. Hoffmann-La Roche A.-G, Switz.) 62
136. Iwaoka M, Takemoto S, Tomoda S (2002) J Am Chem Soc 124:10613
137. Mangelsdorf DJ, Evans RM (1995) Cell 83:841
138. Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fujita T, Kawamastu Y (1982) Chem Pharm Bull 30:3563
139. Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T, Kawamastu Y (1982) Chem Pharm Bull 30:3580
140. Hulin B, McCarthy PA, Gibbs EM (1996) Curr Pharm Des 2:85
141. Sohda T, Momose Y, Meguro K, Kawamastu Y, Sugiyama Y, Ikeda H (1990) Arzneim Forsch 40:37
142. Sohda T, Mizuno K, Momose Y, Ikeda H, Fujita T, Meguro K (1992) J Med Chem 35:2617
143. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H (1989) J Med Chem 32:421
144. Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, Lamphere CH, Lewis DM, Rizzi JP (1992) J Med Chem 35:1853
145. Parks DJ, Tomkinson NCO, Villeneuve MS, Blanchard SG, Willson TM (1998) Bioorg Med Chem Lett 8:3657
146. Sohda T, Mizuno K, Kawamastu Y (1984) Chem Pharm Bull 32:4460
147. Weatherman RV, Fletterick RJ, Scanlan TS (1999) Annu Rev Biochem 68: 559
148. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Nature 395:137
149. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A (1998) J Biol Chem 273:31108
150. Yanagisawa H, Takamura M, Yamada E, Fujita S, Fujiwara T, Yachi M, Isobe A, Hagiwara Y (2000) Bioorg Med Chem Lett 10:373
151. Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A (2001) J Mol Graph Model 19:536
152. Murakami K, Tobe K, Ide T, Monchizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T (1998) Diabetes 47:1841
153. Desai RC, Han W, Metzger EJ, Bergman JP, Gratale DF, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Heck JV, Sahoo SP (2003) Bioorg Med Chem Lett 13: 2795
154. Desai RC, Gratale DF, Han W, Koyama H, Metzger EJ, Lombardo VK, MacNaul KL, Doebber TW, Berger JP, Leung K, Franklin R, Moller DE, Heck JV, Sahoo SP (2003) Bioorg Med Chem Lett 13:3541
155. Khanna S, Sobhia ME, Bharatam PV (2005) J Med Chem 48:3015
156. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe Jr RT, Mckee DD, Moore LB, Willson TM (2001) Proc Natl Acad Sci USA 98:13919
157. Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y (1984) J Pharmacol Exp Ther 229:226
158. Chung SSM, Ho ESM, Lam KSL, Chung SK (2003) J Am Soc Nephrol 14:S233
159. Kador PF (1988) Med Res Rev 8:325
160. Fresneau P, Cussac M, Morand J, Szymonski B, Tranqui D, Leclerc G (1998) J Med Chem 41:4706
161. Wilson DK, Bohren KM, Gabbay KH, Quioco FA (1993) Proc Natl Acad Sci USA 90:9847
162. Mimura T, Kohama Y, Kuwahara S, Yamamoto K, Komiyama Y, Satake M, Chiba Y, Miyashita K, Tanaka T, Imanishi T, Iwata C (1988) Chem Pharm Bull 36:1110
163. Sataka M, Chiba Y, Kohama Y, Yamamoto K, Okabe M, Mimura T, Imanishi T, Iwata C (1989) Experientia 45:1110

164. Sato M, Kawashima Y, Goto J, Yamane Y, Chiba, Y, Jinno S, Satake M, Imanishi T, Iwata C (1994) *Chem Pharm Bull* 42:521
165. Ezumi K, Yamakawa M, Narisada M (1990) *J Med Chem* 33:1117
166. Patscheke H, Stegmeier K (1984) *Thromb Res* 33:277
167. Arita H, Nakano T, Hanasaki K (1989) *Prog Lipid Res* 28:273
168. Coleman RA, Sheldrick RLG (1989) *Br J Pharmacol* 96:688
169. Lacan F, Verache-Lembege M, Vercauteren J, Leger JM, Masereel B, Donge JM, Nuhrich A (1999) *Eur J Med Chem* 34:311
170. Ezumi K, Yamakawa M, Narisada M (1990) *J Med Chem* 33:1117
171. Fukumoto S, Shiraishi M, Terashita ZI, Ashida Y, Inada Y (1992) *J Med Chem* 35:2202
172. Saxena AK, Pandey SK, Seth, P, Singh MP, Dikshit M, Carpy A (2001) *Bioorg Med Chem* 9:2025
173. Barreca ML, Balzarini J, Chimirri A, De Clercq E, De Luca L, Holtje HD, Holtje M, Monforte AM, Monforte P, Pannecouque C, Rao A, Zapalla M (2002) *J Med Chem* 45:5410
174. Jonckheere AJ, De Clercq E (2000) *Med Res Rev* 20:129
175. Tantillo JPC, Ding A, Jacobomolina RG, Nanni PL, Boyer SH, Hughes R, Pawels K, Anderis PAJ, Arnold E (1994) *J Mol Biol* 243:369
176. De Clercq E (1993) *Med Res Rev* 13:229
177. Hajos G, Riedi S, Monar J, Szabo D (2000) *Drugs Fut* 25:47
178. Garg R, Gupta SP, Gao H, Babu MS, Debnath AK, Hansch C (1999) *Chem Rev* 99:3525
179. Schaefer W, Friebe WG, Leinert M, Merttens A, Poll T, Von der Saal W, Zilch H, Nuber H, Ziegler ML (1993) *J Med Chem* 36:726
180. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) *J Comput Chem* 19:1639
181. Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB (2004) *QSAR Comb Sci* 23:234
182. Prabhakar YS, Rawal RK, Gupta MK, Solomon VR, Katti SB (2005) *Combinatorial Chemistry & High Throughput Screening* 8:431
183. Roy K, Leonard T (2005) *QSAR Comb Sci* 24:279
184. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zapalla M (2004) *Il Farmaco* 59:33
185. Barreca ML, Chimirri A, De Clercq E, De Luca L, Monforte AM, Monforte P, Rao A, Zapalla M (2003) *Il Farmaco* 58:259
186. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappala M (2003) *Il Farmaco* 58:115
187. Barreca ML, Chimirri A, De Luca L, Monforte AM, Monforte P, Rao A, Zapalla M, Balzarini J, De Clercq E, Pannecouque C (2001) *Bioorg Med Chem Lett* 11:1793
188. Fujita T, Ban T (1971) *J Med Chem* 14:148
189. Rawal RK, Solomon VR, Prabhakar YS, Katti SB (2005) *Combinatorial Chemistry & High Throughput Screening* 8:439
190. Rawal RK, Prabhakar YS, Katti SB (2005) *Bioorg Med Chem* 13:6771
191. Prabhakar YS, Jain P, Khan ZK, Haq W, Katti SB (2003) *QSAR Comb Sci* 22:456
192. Eng G, Whalen D, Musingarimi P, Tierney J, De Rosa M (1998) *Appl organomet Chem* 12:25
193. Zou XJ, Jin GY, Zhang ZX (2002) *J Agri Food Chem* 50:1451
194. Zou XJ, Lai LH, Jin GY, Zhang ZX (2002) *J Agri Food Chem* 50:3757
195. Roeder T, Nathanson JA (1993) *Neurochem Res* 18:921
196. Roeder T, Gewecke M (1990) *Biochem Pharmacol* 39:1793
197. Roeder T (1992) *Life Sci* 50:21

198. Roeder T (1995) *Br J Pharmacol* 114:210
199. Roeder T (1990) *Eur J Pharmacol* 191:221
200. Jennings KR, Kuhn DG, Kukel CF, Trotto SH, Whiteney WK (1988) *Pestic Biochem Physiol* 30:190
201. Ismail SMM, Baines RA, Downer RGH, Dekeyser MA (1996) *Pestic Sci* 46: 163
202. Hirashima A, Yoshii Y, Eto M (1992) *Pestic Biochem Physiol* 44:101
203. Hirashima A, Tomita J, Pan C, Taniguchi E, Eto M (1997) *Bioorg Med Chem* 5:2121
204. Hirashima A, Yoshii Y, Eto M (1992) *Biosci Biotech Biochem* 56:1062
205. Hirashima A, Yoshii Y, Eto M (1994) *Biosci Biotech Biochem* 58:1206
206. Pan C, Hirashima A, Tomita J, Kuwano E, Taniguchi E, Eto M (1997) *J Sci Biol Chem* **1**: www.netsci-journal.com/97v1/97013/index.htm
207. Raina AK (1993) *Ann Rev Entomol* 38:320
208. Ma PWK, Roelofs W (1995) *Insect Biochem Molec Biol* 25:467
209. Fabrias G, Barrot M, Camps F (1995) *Insect Biochem Molec Biol* 25:655
210. Zhu J, Millar J, Loefstedt C (1995) *Archs Insect Biochem Physiol* 30:41
211. Jurenka RA (1996) *Arch Insect Biochem Physiol* 33:245
212. Rafaeli A, Gileadi C (1997) *Invertebrate Neuroscience* 3:223
213. Hirashima A, Pan C, Katafuchi Y, Taniguchi E, Eto M (1996) *J Pestic Sci* 21:419
214. Hirashima A, Shinkai K, Kuwano E, Taniguchi E, Eto M (1998) *Biosci Biotech Biochem* 62:1179
215. Rafaeli A, Gileadi C, Hirashima A (1999) *Pestic Biochem Physio* 65:194
216. Hirashima A, Morimoto M, Kuwano E, Eto M (1999) *Bioorg Med Chem* 7:2621
217. Clifford KH (1980) *Eur J Biochem* 106:337
218. Sacktor BS, Wormser-Shavit E (1966) *J Biol Chem* 241:634
219. Qian X, Liu Z, Li Z, Song G (2001) *J Agri Food Chem* 19:5279

Figure legends

Fig 1. Structure and numbering of Thiazolidine

Fig 2. Some representative chemical transformations of thiazolidine

Fig. 3

Fig. 4

Fig. 5. 3,3'-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4-thiazolidinone. (Reprinted with permission from ref. [85] Copyright 2003 Elsevier Ltd.)

Fig. 6. Entrance view of the *SS* isomer of 3,3'-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4-thiazolidinones into the COX-2 (**a**) and COX-1 (**b**) binding sites. In this **A** and **B** refer to thiazolidinone moieties as shown in Fig. 5. The steric effect of the non-conserved residue at position 523 (valine in **a** and isoleucine in **b**) is reported to be crucial for the distinctive recognition of this compound between COX-1 and COX-2 isoenzymes. (Reprinted with permission from ref. [85]. Copyright 2003 Elsevier Ltd.)

Fig. 7

Fig. 8

Fig. 9

Fig. 10

Fig. 11. Structures of thiazole and benzthiazole derivatives

Fig. 12

Fig. 13

Fig. 14

Fig. 15

Fig. 16. Strategy adopted in the identification of thiazoles (**e**) as potential NPY5 receptor antagonists from the virtual screening of 3D-pharmacophore (**d**) (Reprinted with permission from ref. [130] Copyright 2005 Elsevier Ltd.) developed from three dissimilar seed structures (compounds **a-c**). From of this strategy compound **f** has been identified and found to show mouse NPY5 receptor inhibition (IC_{50}) at 40nM.

Fig. 17. Mapping of the 3D pharmacophore hypothesis onto compounds **a** and **f** (Fig. 16). The trigonal substitution pattern around C_{ar} is allowed to rotate yielding a novel scaffold in the 3D virtual screening campaign (the match is highlighted by the dashed rectangle). (Reprinted with permission from ref. [130], Copyright 2005 Elsevier Ltd.)

Fig. 18 Conformations corresponding to the minimum energies for the thiazole isomers **g** and **h**. The arrows represent the torsional angles sampled in both isomers.(Reprinted with permission from ref. [131] Copyright 2005 Elsevier Ltd.)

Fig. 19 Primary structural requirements of thiazolidinediones (TZDs) for PPAR γ agonistic activity

Fig. 20 Ligand (Rosiglitazone)-enzyme (PPAR γ) crystal structure where the ligand is shown in the binding domain of PPAR γ (Reprinted with permission from ref. [151], Copyright 2001 Elsevier Science Inc.).

Fig. 21

Fig. 22

Fig. 23

Fig. 24

Fig. 25 Superimposition of selected minimum energy conformers of *o*-, *m*- and *p*-phenoxyacetic acid analogues of dihydrothiazoles (*o-e*, *p-e* and *m-e*, shown in dotted lines) on the folded conformation of sulotroban (shown in solid lines) (Reprinted with permission from ref. [169], Copyright 1999 Elsevier Paris.).

Fig. 26

Fig. 27. The 'butterfly like model' derived from the common 3D superimposition of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (**TIBO**), Nevirapine and (S)-(-)9b-phenyl-2,3-dihydrothiazolo[2,3-3]isoindol-5-(9bH)-one (compound **b**, Fig.25) (Reprinted with permission from ref. [179], Copyright 1993 American Chemical Society).

Fig. 28

Fig. 29

Fig. 30. Apex3D QSAR models of thiazolidines (Table 21) for their activity against *Cryptococcus neoformans* (CN) (Eq.40), *Tricophyton mentagrophyte* (TM) (Eq.41) and *Aspergillus fumigatus* (AF) (Eq.42). In the molecular superimposition, circles identified with arrows represent the locations of the biophoric centers (BC).

Fig. 31. A composite representation of the thiazolidines' superimposition pattern corresponding to Eqs. 40 - 42 in 2D-structure space. Annotations in italic capital letters *A* and *B* stand for the most probable locations of biophoric centers of equation 40 (also equation 41) and equation 42 respectively and the italic small case *a*, *b* and *c* stand for secondary site locations of equations 40, 41 and 42 respectively. The subscripts of annotations represent the *i*th center/ site. The most probable atoms for biophoric centers: *A*₁ is O, *A*₂ is O or S, *A*₃ is N, *C*₁ is N, *C*₂ is O, and *C*₃ is ring center. Biophore distances: *A*₁-*A*₂ is 4.7415)A°(sd, 0.1831), *A*₂-*A*₃ is 2.4872)A°(sd, 0.1657), *A*₁-*A*₃ is 3.5598)A°(sd, 0.1635), *C*₁-*C*₂ is 2.2790)A°(sd, 0.0279), *C*₂-*C*₃ is 5.7242)A°(sd, 0.3156) and *C*₁-*C*₃ is 3.9253)A°(sd, 0.1330). The suffixes pi(π), s, HA, or HD, of *a*, *b* and *c* indicate the nature of the secondary site, as hydrophobic, steric, hydrogen acceptor or hydrogen donor, respectively. The prefixed negative sign, if any, of *a*, *b* and *c* indicates the sign of the *i*th site coefficient in the regression equation. A prime sign on any annotation (lower or upper case) indicates the alternative location of the corresponding site (Reprinted with permission from ref. [191]. Copyright 2003 WILEY-VCH Verlag GmbH & Co.).

Fig. 32

Fig. 33 Alignment and superposition models of 5-[1-aryl-1,4-dihydro-6-methylpyridazin-4-one-3-yl]-2-arylamino-1,3,4-thiadiazoles and corresponding oxadiazoles in CoMFA. (Reprinted with permission from ref.[194], Copyright 2002 American Chemical Society).

Fig. 34

Fig. 35

Fig. 36

Fig. 37

Schemes legends

Scheme 1. General synthesis of thiazolidine

Scheme 2

Scheme 3. General synthesis of thiazolidine-4-carboxylic acid

Scheme 4. A solid phase synthetic protocol of thiazolidine derivatives [13]

Scheme 5. A synthesis of thiazolidine-4-one derivatives

Scheme 6. Synthesis of thiazolidine-4-one derivatives in DCC/HBTU protocol [27,28]










Scheme 7. A solid phase synthesis of thiazolidin-4-ones derivatives [29]

Scheme 8











Scheme 9. Different chemical transformations of thiazolidin-4-ones








Tables

Table 1. Diverse biological responses of thiazolidine derivatives [4]

No.	Names ^a	Chemical Structure	Use
1	Ralitoline ^{s,b}		Anticonvulsant
2	Timiridine esilate ^s		Antidepressant
3	Spiclomazine ^s		Psychotropic
4	Piprozolin		Choleretic
5	Rentiapril [#]		Antihypertensive (ACE inhibitor)
6	Dexetozoline ^s		Antihypertensive
7	Etozolin ^s		Antihypertensive, Diuretic
8	Ozolinone [#]		Diuretic
9	Tizolemide ^s		Diuretic

10	Timofibrate ^s		Antihyperlipidemic
11	Metibride ^s		Antihyperlipidemic
12	Carbolidine		Mucolytic
13	Telmestaine ^s		Mucolytic
14	Letosteine [#]		Mucolytic
15	Alonacic ^s		Mucolytic
16	Neosteine [#]		Mucolytic
17	Guaisteine ^s		Antitussive
18	Thiadrine		Antitussive, Anti-asthmatic
19	Mezolidon		Antiulcer agent

20	Thiazolidomycin		Antibiotic for several streptomyces species
21	Ferrithiocin		Promotes antibacterial activity of cephalosporins
22	Fezatione		Antifungal Antitrichophytic
23	Antazonite [#]		Parasiticide, Anthelmintic
24	Cyamiazole		Acaricide, Ectoparasiticide
25	Nitrodan [#]		Anthelmintic (veterinary)
26	Libecilide ^s		Anti-allergic (inhibits penicillin induced antibodies)
27	Pioglitazone ^s		Oral hypoglycemic agents
28	Troglitazone ^s		Oral hypoglycemic agents
29	Draglitazone ^s		Oral hypoglycemic agents

30	Englitazone ^s		Oral hypoglycemic agents
31	Ciglitazone ^s		Oral hypoglycemic agents
32	Timonacic ^s		Heptoprotectant Antineoplastic
33	Tidiacic ^s		Treatment of liver disorders
34	Epatrestat ^s		Aldose reductase inhibitor
35	Pidotimod ^s		Immunomodulator
36	Benpenolisin ^s		Diagnostic aid (penicillin sensitive)

^a, names not protected under a registered trademark

^b, \$ for WHO recommended non-proprietary names and # for WHO unprotected non-proprietary names

Table 2. COX inhibitory activity of 2-[4-(thiazole-2-yl)phenyl]propionic acid derivatives (Fig. 3) [80].

No.	R ₁	R ₂	R ₃	pI ₅₀ ^b	
				obsd	cald ^c
1	H	H	H	5.56	6.04
2	F	H	H	6.60	6.51
3	Cl	H	H	6.70	6.81
4	Br	H	H	7.00	6.78
5	CF ₃	H	H	6.52	6.58
6	Me	H	H	5.70	6.16
7	OMe	H	H	5.28	5.60
8	SMe	H	H	6.52	6.32
9	OH	H	H	6.22	6.18
10	NO ₂	H	H	5.54	5.61
11	NH ₂	H	H	6.00	6.02
12	H	Me	H	6.14	6.17
13	H	Et	H	5.52	5.28
14	H	<i>i</i> -Pr	H	4.79	4.16
15	H	Bu	H	3.98	4.13
16	H	acetyl	H	3.98	3.33
17	H	Ph	H	4.44	4.14
18	H	vinyl	H	5.68	5.45
19	H	allyl	H	4.89	4.63
20	H	CH ₂ OH	H	4.80	4.55
21	H	CH ₂ OMe	H	4.52	4.29
22	H	CONH ₂	H	3.12	3.75
23	H	CONHMe	H	2.99	3.08
24	H	CONMe ₂	H	3.04	3.13
25	H	CF ₃	H	5.09	5.01
26	H	H	Me	5.26	5.86
27	H	H	Et	5.49	5.68
28	H	Me	Me	6.00	5.92
29	H	Et	Me	4.99	4.98
30 ^a	H	CH ₂ CH ₂	CH ₂	6.15	4.82
31 ^a	H	CH ₂ CH ₂	CH ₂ CH ₂	6.15	4.72
32	F	Me	H	7.00	6.64
33	F	Et	H	5.92	5.75
34	F	<i>i</i> -Pr	H	4.47	4.63
35	F	Bu	H	4.29	4.60
36	F	H	Me	6.52	4.33
37	F	H	Et	6.05	6.15
38	F	Me	Me	6.70	6.39
39	F	Et	Me	5.30	5.45
40	Cl	Me	H	7.00	6.94
41	Cl	Et	H	6.15	6.05
42	Cl	<i>i</i> -Pr	H	4.47	4.93
43	Cl	Bu	H	4.21	4.90
44	Cl	H	Me	7.22	6.63
45	Cl	H	Et	6.70	6.45
46	Cl	Me	Me	6.10	6.69
47	Cl	Et	Me	5.92	5.75

^a, compounds are not included in regression analysis study.

^b, Cyclooxygenase inhibitory activity

^c, calculated activity by Eq. 3

Table 3. Molecular descriptors and COX-2 Inhibitory activities of thiazolone and oxazolone derivatives (Fig. 4) [84]

No.	X	R ₁	R ₂	R ₃	x ₁	x ₇	x ₂₉	x ₅₂	pIC ₅₀ ^a	
									obsd	calcd ^b
1	NMe	<i>t</i> -Bu	H	NHC(=NH)NH ₂	15.73	-8.87	3.22	0	4.09	3.98
2	O	<i>t</i> -Bu	H	NHOEt	15.20	0	1.12	0	4.10	4.78
3	S	<i>t</i> -Bu	H	NHCN	14.71	0	2.65	-0.76	4.26	4.55
4	O	<i>t</i> -Bu	H	OH	14.73	0	-1.51	0	4.47	4.36
5	O	<i>t</i> -Bu	H	NHO-allyl	15.33	0	0.69	0	4.59	4.69
6	S	<i>t</i> -Bu	H	NHC(=NH)NH ₂	14.87	0	3.51	-0.78	4.68	4.67
7	S	<i>t</i> -Bu	H	NMeOMe	16.86	-8.20	7.67	0	4.74	4.74
8	S	<i>t</i> -Bu	Me	NHC(=NH)NH ₂	16.28	0	4.61	-0.79	4.92	4.73
9	O	<i>t</i> -Bu	H	NHC(=NH)NH ₂		0	-1.28	1.18	5.29	5.23
10	S	<i>t</i> -Bu	H	OH	14.73	0	2.21	0	5.33	5.00
11	S	<i>t</i> -Bu	H	NHOEt	14.87	0	6.44	0	5.49	5.70
12	S	<i>t</i> -Bu	H	NHO-allyl	15.35	0	5.90	0	5.57	5.59
13	S	<i>t</i> -Pr	H	NHC(=NH)NH ₂	15.48	0	3.39	-0.76	5.74	5.56
14	S	<i>t</i> -Bu	H	Sme	4.89	0	7.83	0	5.74	5.92
15	S	<i>t</i> -Bu	H	NHOMe	15.57	0	6.12	0	5.77	5.64
16	S	<i>t</i> -Bu	H	SH	15.33	0	5.33	0	5.82	5.54
17	S	<i>t</i> -Bu	H	NHOH	14.96	0	5.07	0	5.82	5.49
18	S	<i>i</i> -Pr	H	NHOMe	14.92	0	5.99	0	6.24	6.53
19	Indomethacin				0.13	-2.31	0.13	0	0.13	5.64
20	SC-58125				0	-0.18	5.15	0	5.15	6.66
21	NS-398				0	0.01	0.00	0	0.00	6.10

^a, COX-2 inhibitory activity

^b, Eq. 4

Table 4. Geometrical descriptors,^a E/L (Enzyme/Ligand) interaction and ligand internal energies [85]

Isomer	Isozyme	N-C-C-N dihedral angle (°)	Ar/Ar distance (Å)	Enzyme/ligand interaction energy (kcal/mol)	Ligand internal energy (kcal/mol)
RR	COX-1	-163.15	5.706	3.73	41.88
	COX-2	-77.01	4.478	-3.31	10.66
SS	COX-1	-134.85	6.124 ^b	14.74	53.01
	COX-2	-154.59	7.443	-47.15	12.06
RS	COX-1	-83.80	7.824	-37.93	25.62
	COX-2	59.37	4.603	-46.88	28.93

^a, global minimum conformations within the enzyme clefts.

^b, folded conformation with the phenyl of moiety 'A' in close proximity to the thiazolidinone of moiety 'B' (see Fig.5).

Table 5. 4-alkyl/aryl-2-amido thiazoles in modeling the Nitric oxide (NO) and glycosaminoglycans (GAGs) release inhibitory activity (Fig. 7) [87]

No.	R	n	N(R ₁) ₂
1	Ph	1	NMe ₂
2	Ph- OMe	1	Pyrrolidine
3	Ph-OMe	1	Piperidine
4	CH ₂ COOEt	1	Piperidine
5	H	2	Pyrrolidine
6	Ph	2	Pyrrolidine
7	Ph- <i>p</i> OMe	2	NMe ₂
8	Ph- <i>p</i> OMe	2	Pyrrolidine
9	CH ₂ COOEt	2	Morpholine

Table 6. Physicochemical properties and carrageenan mice paw edema (%CPE) inhibitory activity of 4-alkyl/aryl-2-amido thiazoles (Fig.8) [91].

No	R	X	n	RM	clog	PclogD _{7.4}	SURF	pKa	log %CPE ^a	
									obsd	cald ^b
1	H	NMe ₂	1	-0.54	0.31	0.13	53.5	7.11	1.45	1.64
2	H	<i>c</i> N(CH ₂) ₄ NMe	1	-0.12	1.10	0.9	56.8	7.17	1.85	1.84
3	Me	NMe ₂	1	-0.57	0.81	0.63	50.5	7.11	1.58	1.55
4	Me	NEt ₂	1	-0.53	1.71	0.81	47.2	8.24	1.37	1.42
5	Ph	NMe ₂	1	-0.27	2.41	2.24	52.3	7.09	1.72	1.68
6	Ph	<i>c</i> NC ₄ H ₈	1	-0.14	3.29	2.40	58.8	8.22	1.69	1.95
7	<i>p</i> -OMePh	NMe ₂	1	-0.26	2.43	2.42	49.7	5.55	1.54	1.56
8	<i>p</i> -OMePh	<i>c</i> NC ₄ H ₈	1	-0.16	3.30	3.23	56.8	6.68	1.74	1.83
9	<i>p</i> -OMePh	<i>c</i> NC ₅ H ₁₀	1	-0.03	3.86	3.86	53.6	5.73	1.73	1.64
10	<i>p</i> -Cl-Ph	<i>c</i> NC ₅ H ₁₀	1	-0.3	4.56	4.56	57.1	4.33	1.67	1.70
11	CH ₂ OCOEt	NMe ₂	1	-0.60	0.66	0.29	52.3	7.09	1.65	1.60
12	CH ₂ OCOEt	NEt ₂	1	-0.51	1.56	0.64	49.4	8.22	1.73	1.51
13	CH ₂ OCOEt	<i>c</i> NC ₄ H ₈	1	-0.45	1.54	0.27	58.8	8.22	1.55	1.88
14	CH ₂ OCOEt	<i>c</i> NC ₅ H ₁₀	1	-0.54	2.09	1.49	55.7	7.25	1.78	1.82
15	CH ₂ OCOEt	<i>c</i> N(CH ₂) ₄ O	1	-0.59	0.82	0.40	57.4	5.17	1.69	1.83
16	H	<i>c</i> NC ₄ H ₈	2	0.14	1.38	-0.87	60.3	9.65	1.81	1.81
17	Ph	<i>c</i> NC ₄ H ₈	2	-0.26	3.00	0.55	56.8	9.85	1.84	1.82
18	<i>p</i> -OMePh	NMe ₂	2	0.13	2.66	2.45	48.5	7.18	1.73	1.51
19	<i>p</i> -OMePh	<i>c</i> NC ₄ H ₈	2	0.26	3.50	2.7	54.6	8.31	1.75	1.76
20	<i>p</i> -OMePh	<i>c</i> NC ₅ H ₁₀	2	-0.53	4.06	3.78	52.3	7.36	1.60	1.59
21	<i>p</i> -OMePh	<i>c</i> N(CH ₂) ₄ O	2	-0.34	2.79	2.7	53.6	6.80	1.74	1.72
22	CH ₂ OCOEt	NMe ₂	2	-0.2	0.89	-0.72	50.7	8.72	1.72	1.42
23	CH ₂ OCOEt	NEt ₂	2	-0.16	1.87	-0.76	48.3	9.85	1.81	1.31
24	CH ₂ OCOEt	<i>c</i> NC ₄ H ₈	2	-0.03	1.73	-1.13	56.8	9.85	1.54	1.61
25	CH ₂ OCOEt	<i>c</i> NC ₅ H ₁₀	2	-0.17	2.29	0.40	54.1	8.88	1.63	1.69
26	CH ₂ OCOEt	<i>c</i> N(CH ₂) ₄ O	2	-0.54	1.02	0.13	55.6	6.80	1.77	1.73

^a, log of percent inhibition of carrageenan-induced edema, log %CPE, in mice

^b, Eq. 8

Table 7. Thiazole and thiadiazole analogues in modeling the Adenosine A₃ receptor antagonistic activity (Fig. 9) [103-105].

	X	Z	R	pK _i ^a			
				obsd	cald ^b	cald ^c	cald ^d
1. (LUF5417)	N	H	4-OMePh	7.09	-	-	7.31
2	CH	H	Me	7.74	8.03	7.89	7.65
3	CH	H	(Me ₃ C)O	5.29	5.22	5.22	5.59
4	CH	H	NCCH ₂	6.69	7.13	6.50	7.88
5	CH	4-Cl	Me	7.29	7.04	7.48	7.31
6	CH	4-Cl	PhCH ₂	7.00	6.74	7.07	6.55 ^e
7	CH	4-MeO	Me	8.52	8.42	8.24	7.88
8	CH	3-MeO	Me	8.39	8.42	8.39	7.89
9	CH	2MeO	Me	7.09	7.00	7.06	7.47
10	CH	4-MeO	Me	6.28	6.73	6.35	5.93
11	CH	4-MeO	Et	8.62	7.88	8.26	8.09
12	CH	4-MeO	Pr	8.11	8.04	8.28	8.00
13	CH	4-MeO	<i>i</i> -Pr	7.79	7.39	7.80	7.43
14	CH	4-MeO	NCCH ₂	7.61	8.18	7.57	8.17
15	CH	4-MeO	<i>t</i> -Bu	7.50	7.20	7.67	7.62
16	CH	4-MeO	(Me ₃ C)O	5.49	5.50	5.61	6.06 ^e
17	CH	4-MeO	Ph	7.54	7.29	7.62	6.83 ^e
18	CH	4-MeO	PhCH ₂	7.85	7.43	7.85	6.96 ^e
19	CH	4-MeO	PhCH ₂ CH ₂	7.54	7.08	7.51	7.36
20	CH	4-MeO	<i>p</i> -MeOPhCH ₂	5.94	7.16	5.97	7.24
21	CH	4-MeO	<i>p</i> -MeOPhCH ₂ CH ₂	7.54	6.88	7.49	7.89
22	CH	4-MeO	Ph ₂ CH	6.28	6.97	6.29	6.13
23	CH	4-MeO	Ph ₂ CHCH ₂	6.40	6.41	6.40	6.58
24	CH	4-MeO	2-Furan	7.50	7.68	7.40	6.63
25	CH	4-MeO	Thiophene-2-CH ₂	7.49	7.24	7.47	6.45 ^e
26	CH	4-MeO	2-Thiophene	7.16	7.28	7.38	6.67
27				6.43			6.81
28	N	H	CH ₃	8.64	8.92	8.62	8.57 ^e
29	N	H	PhCH ₂	7.10	7.51	6.92	6.99
30	N	4-MeO	Me	9.10	8.88	9.08	8.78
31	N	4-MeO	PhCH ₂	7.62	7.52	7.59	7.66
32	N	4-MeO	Et	8.95	8.82	9.10	8.60

^a, Adenosine A₃ receptor antagonistic activity

^b, Eq. 10, compounds 1 and 27 are not in the regression, ref. 103

^c, Eq. 14, compounds 1 and 27 are not in the regression, ref. 104

^d, Eq. 15, ref. 105

^e, test set compound

Table 8. Thiazole and thiadiazole analogues in modeling the Adenosine A₁ receptor antagonistic activity (Fig. 9) [105].

No.	X	Y	R	pK _i ^a	
				obsd	calcd ^b
1	CH	CH	4-OMePh	7.12	
2	N	CH	4-OMePh	7.49	7.50
3	CH	N	Ph	5.77	5.68
4	CH	N	4-ClPh	6.70	6.32
5	CH	N	4-IPh	5.62	6.20
6	CH	N	4-MePh	5.80	5.94
7	CH	N	4-O MePh	5.49	5.96 ^c
8	CH	N	3,4-diClPh	5.80	6.15 ^c
9	CH	N	3-ClPh	5.77	5.58
10	CH	N	4-NO ₂ Ph	5.82	6.00
11	CH	N	4-OCH(Me) ₂ Ph	5.24	5.54
12	CH	N	Cyclopentyl	6.04	5.47
13	N	CH	Ph	7.51	7.47
14	N	CH	4-ClPh	7.39	7.90 ^c
15	N	CH	4- MePh	7.52	7.39
16	N	CH	4-OHPH	8.14	8.30
17	N	CH	4-OCH ₂ CO ₂ Ph	7.00	7.12
18	N	CH	Cyclohexyl	5.85	6.79
19	N	CH	(<i>trans</i>) 4-OMe-cyclohexyl	7.49	6.77
20	N	CH	(<i>cis</i>) 4-OMe-cyclohexyl	6.96	6.81
21	N	CH	(<i>trans</i>) 4-OH-cyclohexyl	7.70	7.27 ^c
22	N	CH	(<i>cis</i>) 4-OH-cyclohexyl	7.38	7.15
23	N	CH	NHPh	6.00	5.96
24	CH	N	NHPh	6.03	5.66 ^c
25	CH	CH	Ph	7.41	7.52
26	CH	CH	3-ClPh	7.07	7.31
27	CH	CH	4-BrPh	7.48	7.18 ^c
28	CH	CH	4-ClPh	7.74	7.52
29	CH	CH	4-NO ₂ Ph	7.66	7.11
30	CH	CH	4- MePh	7.44	7.32
31	CH	CH	4-C(Me) ₃ Ph	5.87	6.51
32	CH	CH	4-CF ₃ Ph	6.78	6.78
33	CH	CH	3,4-diClPh	7.23	7.30
34	CH	CH	2,4-diClPh	7.24	7.17

^a, Adenosine A₁ receptor antagonistic activity

^b, Eq. 16, ref. 105

^c, test set compound

Table 9. Physicochemical properties and anti-histaminic activity of 2,3-disubstituted thiazolidin-4-ones derivatives (Fig.10) [109]

No	R	ΣF	π_4	pA_2^a	
				obsd	cald ^b
1	H	0.00	0.00	7.4	7.4
2	4-F	0.43	0.14	7.1	6.5
3	4-Cl	0.41	0.71	5.6	7.1
4	4-Br	0.44	0.86	7.4	7.2
5	4-Me	-0.04	0.56	8.3	8.1
6	4-OMe	0.26	-0.02	5.0	6.7
7	4-NO ₂	0.67	-0.28	5.2	5.4
8	4-NH ₂	0.02	-1.23	6.0	6.1
9	4- <i>i</i> Pr	-0.05	1.53	8.7	9.1
10	3-F	0.43	0.00	6.4	6.3
11	3-Cl	0.41	0.00	6.2	6.4
12	3-Br	0.44	0.00	6.4	6.3
13	3-Me	-0.04	0.00	7.7	7.5
14	3-OMe	0.26	0.00	6.4	6.7
15	3-NO ₂	0.67	0.00	5.4	5.7

^a, 50% inhibition of histamine (H₁) activity in isolated guinea pig ileum (relative to mepyramine)

^b, Eq. 18

Table 10. Thiazole and benzthiazole derivatives in modeling the anti-histaminic activity (Fig.11), [111,112]

No	R	n	pA ₂ ^a		
			obsd	cald ^b	cald ^c
1	H	-	4.44	4.10	4.53
2	3-Me	-	4.00	4.18	3.83
3	3-F	-	4.53	4.79	4.62
4	3-Cl	-	4.82	5.02	4.78
5	3-Br	-	4.65	5.20	4.92
6	3-OMe	-	4.14	4.13	4.37
7	H	-	5.88	5.72	5.87
8	3-F	-	6.15	6.22	5.69
9	3-Cl	-	6.38	5.96	6.04
10	4-F	-	5.99	5.74	5.78
11	4-Br	-	5.87	6.01	6.19
12	H	-	5.98	5.78	6.10
13	Me	3	5.70	5.56	5.92
14	H	2	5.82	5.74	5.46
15	Me	2	5.60	5.25	5.60
16	-CH ₂ -Ph-4-Me	3	5.99	6.32	6.23
17	-C ₂ H ₄ -Ph-4-Me	2	6.08	6.14	6.12
18	-CH ₂ -Ph	2	5.77	5.90	5.74

^a, 50% inhibition of histamine (H₁) antagonist activity (isolated guinea pig ileum) relative to temelastine

^b, Eq. 20, ref.111 ^c, Eq. 21, ref.112

Table 11. 4-indolyl, 2-guanidinothiazole derivatives in modeling the H⁺K⁺-ATPase inhibitory activity (Fig 13) [120]

No.	R ₁	R ₂	R ₃	IC ₅₀ ^a			
				obsd	Pridected ^b		
					PLS	PCR	BPN
1	H	H	H	9.0	6.0	3.3	8.4
2	C ₇ H ₇	H	H	1.5	1.3	3.2	1.2
3	H	Me	H	7.6	7.9	2.2	7.6
4	H	H	5-OMe	19.0	16.2	4.4	7.2
5	C ₇ H ₇	H	5-OMe	4.3	3.5	3.7	6.4
6	H	H	5-OC ₇ H ₇	1.2	1.3	3.9	1.4
7	C ₇ H ₇	H	5-OC ₇ H ₇	1.8	1.7	3.6	0.61
8	H	H	2-Me	9.0	10.6	3.1	5.2
9	C ₇ H ₇	H	2-Me	1.7	2.2	2.90	1.1
10	H	Me	2-Me, 5-Cl	0.6	0.47	0.97	2.8
11	C ₇ H ₇	Me	2-Me, 5-Cl	1.1	0.74	0.61	0.89
12	C ₇ H ₇	H	4-Me	3.3	3.7	0.87	0.27
13	H	H	5-Me	1.8	2.3	2.9	2.9
14	C ₇ H ₇	H	5-Me	0.94	1.1	2.9	0.57
15	C ₇ H ₇	H	6-Me	1.6	1.5	3.5	2.2
16	H	H	7-Me	7.6	6.7	3.6	6.7
17	C ₇ H ₇	H	7-Me	1.0	1.4	3.4	2.2
18	H	H	5-Cl	1.8	1.5	2.3	1.9
19	C ₇ H ₇	H	5-Cl	0.7	0.87	0.98	0.31
20	H	Me	5-Cl	0.59	0.81	0.8	2.1
21	C ₇ H ₇	Me	5-Cl	0.7	0.63	0.88	0.77
22	H	H	5-Br	0.96	1.1	2.6	1.0
23	C ₇ H ₇	H	5-Br	0.7	0.52	2.3	1.1
24	H	H	5-F	7.4	9.2	4.1	9.9
25	C ₇ H ₇	H	5-F	2.7	3.3	3.9	3.2
26	H	H	5-CO ₂ Me	6.7	5.3	2.4	0.37

27	C ₇ H ₇	H	5-CO ₂ Me	3.1	3.4	2.1	4.2
28	C ₇ H ₇	H	5-NHCOEt	23.8	21.7	5.9	4.0

^a, H⁺K⁺-ATPase inhibitory activity

^b, Predicted activity by leave one out procedure

Table.12 Physicochemical properties and anticonvulsant activity of benzothiazolamines derivatives (Fig. 14), [123]

No	X	45SUBST	π	MR	-logIC ₅₀ ^a	
					obsd	calcd ^b
1	6-OCF ₃ (Riluzole)	0	1.04	0.79	5.39	4.82
2	H	0	0.00	0.10	4.59	4.53
3	6-SMe	0	0.61	1.38	4.80	4.13
4	6-Me	0	0.56	0.56	3.82	4.54
5	6-CHMe ₂	0	1.53	1.50	5.17	4.68
6	6-COOH	0	-0.32	0.69	3.88	-
7	6-SO ₂ Me	0	-1.63	1.35	3.30	3.22
8	6-Cl	0	0.71	0.60	5.17	4.57
9	6-OMe	0	-0.02	0.79	3.30	3.74
10	6-COPh	0	1.05	3.03	3.30	3.96
11	6-SO ₂ NH ₂	0	-1.82	1.23	3.30	3.14
12	6-Br	0	0.86	0.89	4.85	4.50
13	6-NO ₂	0	-0.28	0.74	3.66	4.23
14	6-CF ₃	0	0.88	0.50	5.31	5.04
15	6-F	0	0.14	0.09	3.30	4.30
16	6-OH	0	-0.67	0.28	3.30	3.47
17	6-NH ₂	0	-1.23	0.54	3.30	2.99
18	5-OMe	1	-0.02	0.79	3.30	3.14
19	5-Me	1	0.56	0.56	3.30	3.70
20	5-CF ₃	1	0.88	0.50	4.00	4.02
21	5-COPh	1	1.05	3.03	3.30	3.06
22	4-OMe	1	-0.02	0.79	3.30	2.90
23	4-Me	1	0.56	0.56	3.82	3.63
24	4-Cl	1	0.71	0.60	4.58	3.68
25	4-CF ₃	1	0.88	0.50	3.86	4.10
26	4-Ph	1	1.96	2.54	5.04	-
27	4-Me,5-F	1	0.70	0.66	3.30	3.55
28	4,5-(CHCH) ₂	1	1.30	1.75	3.30	3.49
29	4,6-F ₂	1	0.28	0.18	3.30	3.17
30	4,6-Cl ₂	1	1.42	1.21	3.30	3.67
31	4,6-Me ₂	1	1.12	1.13	3.30	3.59
32	5,6-Me ₂	1	0.99	1.13	3.30	3.56

^a, Sodium flux (NaFl) inhibition

^b, Eq. 22

Table 13. Physicochemical / electronic properties and β_3 - agonist activity of thiazole derivatives (comp. e, Fig. 15) [129]

No	n	R	E_ele	SlogP	SlogP_VSA0	SlogP_VSA8	pEC ₅₀ ^a		
							obsd	cald ^b	Cald ^c
1	0	C ₈ H ₁₇	-0.04	6.87	43.40	119.68	-1.00	-0.92	-0.86
2	0	CH ₃ CONH(CH ₂) ₅	-0.04	4.89	61.41	63.07	-1.70	-1.42	-1.78
3	0	C ₂ H ₄ Ph	-0.05	5.75	43.40	6.47	-1.52	-1.69	-1.46
4	0	CH ₂ -naphthyl	-0.04	6.71	43.40	6.47	-0.70	-0.67	-0.65
5	0	2-benzofuranyl	-0.04	6.38	43.40	6.47	-0.96	-0.88	-0.75
6	0	3-indolyl	-0.04	6.12	43.40	6.47	-0.69	-0.81	-0.86
7	0	3-pyridinyl	-0.04	5.03	43.40	6.47	-1.60	-1.26	-1.44
8	0	2-pyridinyl	-0.04	5.03	43.40	6.47	-1.34	-1.41	-1.52
9	0	3,4-diF-Ph	-0.04	5.91	43.40	6.47	-0.85	-0.91	-1.01
10	0	PhcC ₆ H ₁₁	-0.04	7.76	43.40	81.94	-0.08	-0.22	-0.23
11	0	Ph- <i>t</i> Bu	-0.04	6.93	43.40	6.47	-0.38	-0.40	-0.40
12	0	4-OH-Ph	-0.04	5.34	68.78	6.47	-1.65	-1.91	-1.34
13	0	4-AcNH-Ph	-0.05	5.59	43.40	6.47	-1.65	-1.54	-1.71
14	0	4F-PhCH ₂	-0.04	5.70	43.40	6.47	-0.79	-0.96	-1.13
15	1	C ₈ H ₁₇	-0.04	6.58	61.41	138.55	-0.99	-1.10	-0.99
16	1	CH ₂ -naphthyl	-0.04	6.22	61.41	6.47	-1.08	-0.90	-0.86

^a, β_3 - agonist activity

^b, Eq. 23

^c, Eq. 24

Table 14. Thiazolidinedione and oxazolidinedione derivatives in modeling (CoMFA) PPAR- α , γ and dual (d) binding affinity (comp. a, Fig. 22), [155]

No	X	R ₁	pIC ₅₀ ^a					
			α		γ		(d)	
			obsd	perd	obsd	perd	obsd	perd
1	S	OPh	7.55	7.47	7.24	7.37	14.79	14.79
2 ^b	S	OPh	7.33	-	7.12	-	14.45	
3 ^c	S	OPh	5.30	5.11	6.71	6.78	12.01	12.01
4	S	OPh-4-CH(Me) ₂	5.68	5.76	6.77	6.72	12.45	12.45
5	S	OPhC(Me) ₃	5.0	5.03	6.47	6.49	11.47	11.47
6	S	OPh-4-CH ₂ CH(Me) ₂	5.0	5.05	6.54	6.50	11.54	11.54
7	S	OPh-4-cC ₅ H ₉	5.70	-	6.48	-	12.18	-
8	S	OPh-Ph	5.0	5.07	6.65	6.54	11.65	11.65
9	S	OPh-4Cl	7.0	-	7.14	-	14.14	-
10	S	OPh-4F	7.55	7.25	7.11	7.15	14.66	14.66
11	S	OPh-4OMe	5.59	5.42	6.52	6.75	12.11	12.11
12	S	OPh-4OH	6.02	6.43	7.52	7.22	13.54	13.54
13	S	OPh-3,4-di-Cl ₂	7.17	-	7.19	-	14.36	-
14	S	OPh-3-Me,4-Cl	6.79	6.92	7.25	7.13	14.04	14.04
15	S	OPh-3-Me,4-F	6.95	7.06	7.11	7.22	14.06	14.06
16	S	OcC ₆ H ₁₁	5.85	6.10	7.43	7.27	13.28	13.28
17	S	OcC ₇ H ₁₃	6.68	6.93	7.07	7.18	13.75	13.75
18	S	OcC ₅ H ₉	7.38	7.09	7.20	7.26	14.58	14.58
19	S	COPh	7.05	7.04	7.72	7.66	14.77	14.77
20	S	COPh-4Cl	5.0	-	6.84	-	11.84	-
21	S	3-benzisoxazyl	7.43	7.57	7.52	7.56	14.95	14.95
22	S	COcC ₆ H ₁₁	6.92	6.93	7.19	7.10	14.11	14.11
23	S	CH=cC ₆ H ₁₀	7.21	7.13	6.82	6.94	14.03	14.03
24	S	CH ₂ cC ₆ H ₁₁	7.34	7.31	7.23	7.14	14.57	14.57
25	S	cC ₆ H ₁₁	5.30	-	6.47	-	11.77	-
26	O	cC ₆ H ₁₁	6.54	6.36	6.31	6.17	12.85	12.85

27	O	Ph	5.57	5.78	6.35	6.38	11.92	11.92
28	O	cC ₇ H ₁₃	6.21	6.35	6.19	6.12	12.40	12.40
29	O	cC ₅ H ₉	6.20	-	5.97	-	12.17	-
30	O	4-cyclohexanone	4.82	4.67	5.94	5.86	10.76	10.76
31	O	4-cyclohexanol	4.82	4.85	6.74	6.88	11.56	11.56
32	O	1,1-difluoro-4-cyclohexane	6.23	6.01	6.27	6.35	12.50	12.50
33	O	1,1-dimethyl-4-cyclohexane	5.48	5.33	5.75	5.80	11.23	11.23
34	O	4-tetrahydro-pyran	5.54	5.72	6.12	6.18	11.66	11.66

^a, PPAR α / γ and dual (d) binding affinities

^b, Without propyl group

^c, O-(CH₂)₄-O in place of O-(CH₂)₃-O

Table15. 2-(*N*-aryl-*N*-aroyl)amino-4,5-dihydrothiazoles derivatives in modeling the antithrombotic activity (comp. f, Fig. 23) [172]

No.	R ₁	R ₂	log(P/100-P) ^a		
			obsd	cald ^b	cald ^c
1	2-CF ₃	H	-0.37	-0.37	-0.35
2	4-F	H	-0.22	-0.36	-0.34
3	2,5(OMe) ₂	H	-0.37	-0.33	-0.32
4	2-Cl,6-Me	H	-0.37	-0.37	-0.36
5	2- Me	H	-0.60	-0.50	-0.46
6	2-CF ₃	4-OMe	-0.37	-0.25	-0.26
7	2- Me	4-OMe	-0.37	-0.38	-0.36
8	2,5(OMe) ₂	4-OMe	-0.18	-0.21	-0.22
9	4-F	4-OMe	-0.18	-0.29	-0.24
10	2-Cl,6-Me	2-Me	-0.48	-0.39	-0.39
11	2-CF ₃	2-Me	-0.22	-0.39	-0.38
12	4-F	2-Me	-0.37	-0.37	-0.37
13	4-OMe	2-Me	-0.48	-0.43	-0.41
14	4-Et	4-Cl	-0.18	-0.14	-0.34
15	2-Cl,6-Me	4-Cl	-0.30	-0.17	-0.24
16	4-F	4-Cl	-0.30	-0.19	-0.22
17	2-Me	2-Br	-0.37	-0.30	-0.34
18	H	2-Br	-0.18	-0.29	-0.33
19	2-Cl,6-Me	2-Br	-0.22	-0.18	-0.24
20	2,5(OMe) ₂	4-NO ₂	-0.12	-0.03	-0.01
21	4-NO ₂	4-NO ₂	0.00	0.02	0.03
22	4-F	4-NO ₂	-0.18	-0.06	-0.03
23	2-Me	4-NO ₂	-0.14	-0.20	-0.15
24	2-OMe	4-NO ₂	0.00	-0.11	-0.08
25	4-Cl,3-NO ₂	4-NO ₂	0.26	0.14	0.13

^a, P is percent protection offered, in mice, to thrombotic challenge in comparison to inodmethacin

^b, Eq. 25

^c, Eq. 26

Table 16: 2-(2,6-Dihalophenyl)-3-(substituted pyridin-2-yl)-thiazolidin-4-ones analogues in modeling the HIV-1 RT inhibitory activity (comp. **a**, X= N, Fig. 26) [181]

No.	R''				R'		-logEC ₅₀ ^a	
	6''	3''	5''	4''	2'	6'	obsd	calcd ^b
1	H	H	H	H	Cl	Cl	6.75	6.89
2	H	H	H	H	Cl	F	6.55	6.70
3	H	H	H	H	F	F	6.07	6.53
4	H	H	H	Cl	Cl	Cl	5.75	5.77
5	H	H	H	Cl	Cl	F	5.67	5.56
6	H	H	H	Cl	F	F	5.14	5.41
7	H	H	H	Br	Cl	Cl	5.82	5.83
8	H	H	H	Br	Cl	F	5.91	5.64
9	H	H	H	Br	F	F	5.31	5.47
10	H	Br	H	H	Cl	Cl	6.56	7.24
11	H	Br	H	H	Cl	F	7.19	7.06
12	H	Br	H	H	F	F	7.52	6.88
13	Me	H	H	H	Cl	Cl	-	
14 ^c	Me	H	H	H	F	F	4.27	
15	H	H	Me	H	Cl	Cl	6.83	7.12
16	H	H	Me	H	Cl	F	7.00	6.94
17	H	H	Me	H	F	F	6.60	6.76
18	H	H	H	Me	Cl	Cl	5.85	5.71
19	H	H	H	Me	F	F	5.29	5.34
20	H	Me	H	H	Cl	Cl	7.36	7.12
21	H	Me	H	H	Cl	F	7.27	6.93
22	H	Me	H	H	F	F	7.08	6.76
23	H	Me	Me	H	Cl	Cl	7.04	7.35
24	H	Me	Me	H	Cl	F	7.38	7.17
25	H	Me	Me	H	F	F	7.23	6.99

^a, 50% inhibitory concentration against cytopathic effect of HIV-1 in MT-4 cells

^b, Eq. 27

^c, not included in the analysis

Table 17: 2-(2,6-dihalophenyl)-3-(substituted phenyl)-thiazolidin-4-ones analogues in modeling the HIV-1 RT inhibitory activity (comp. **a**, X= CH, Fig. 26), [181]

No.	R''		R'		-logEC ₅₀ ^a	
	3''	5''	2'	6'	obsd	calcd ^b
26	H	H	Cl	Cl	6.40	6.46
27	H	H	F	F	5.64	5.94
28	Br	H	Cl	Cl	6.21	6.40
29	Br	H	Cl	F	6.19	6.14
30	Br	H	F	F	5.88	5.88
31	Cl	H	Cl	Cl	6.51	6.54
32	Cl	H	Cl	F	6.21	6.28
33	Cl	H	F	F	6.69	6.02
34	Me	H	Cl	Cl	7.09	6.95
35	Me	H	Cl	F	6.67	6.69
36	Me	H	F	F	6.16	6.43
37	Et	H	Cl	Cl	6.81	6.88
38	Et	H	Cl	F	6.67	6.34
39	Et	H	F	F	6.11	6.08
40	MeO	H	Cl	Cl	6.71	6.74
41	MeO	H	Cl	F	6.52	6.71
42 ^c	MeO	H	F	F	4.93	5.65
43	NO ₂	H	Cl	Cl	6.14	5.95
44	NO ₂	H	Cl	F	5.88	5.71
45	NO ₂	H	F	F	5.26	5.45
46	Cl	Cl	Cl	Cl	6.55	6.65
47	Cl	Cl	Cl	F	6.50	6.42
48	Cl	Cl	F	F	6.01	6.17
49	F	F	Cl	Cl	6.89	7.02
50	F	F	Cl	F	6.61	6.42
51	F	F	F	F	6.27	6.16
52	Me	Me	Cl	Cl	6.72	6.72
53	Me	Me	Cl	F	7.06	6.81
54	Me	Me	F	F	6.62	6.55

^a, 50% inhibitory concentration against cytopathic effect of HIV-1 in MT-4 cells

^b, Eq. 30

^c, not included in the analysis

Table 18: 2,3-disubstituted-thiazolidin-4-ones in modeling the HIV-1 RT inhibitory activity
(comp. a, Fig. 26), [183]^a

No.	R''					R'		logEC ₅₀ ^b		-logCC ₅₀ ^c	
	2''	3''	4''	5''	6''	2'	6'	obsd	calcd ^d	obsd	calcd ^e
1	H	Me	H	H	H	Me	Me	-	-	1.44	1.19
2	Cl	Me	H	H	H	F	CF ₃	-	-	1.49	1.52
3	Me	Me	H	H	H	Cl	F	2.83	3.25	1.39	1.75
4	H	Me	H	H	H	MeO	MeO	2.72	2.45	0.68	0.54
5	H	H	H	H	H	F	F	-	-	1.45	1.61
6	H	H	H	H	H	Cl	Cl	-	-	1.51	1.70
7 ^f	H	Me	H	H	H	F	MeO	2.94	2.67	0.84	1.13
8	Cl	H	H	Me	H	F	CF ₃	2.67	2.42	1.03	0.89
9	H	H	H	Me	H	MeO	MeO	2.48	2.72	0.60	0.53
10	H	Me	H	H	H	Me	Me	2.81	2.49	0.55	0.69
11	Cl	Me	H	H	H	F	CF ₃	2.52	2.84	0.92	0.91
12	Me	Me	H	H	H	Cl	F	4.30	3.75	1.42	1.35
13	H	Me	H	H	H	MeO	MeO	2.87	3.16	0.62	0.49
14	H	Br	H	H	H	Me	Me	2.20	2.69	0.57	0.92
15 ^f	H	Br	H	H	H	F	MeO	4.47	3.62	1.00	0.80
16	Cl	Br	H	H	H	F	CF ₃	3.18	2.93	1.06	1.13
17	Me	Br	H	H	H	Cl	F	3.46	3.91	1.68	1.52
18	H	Me	H	Me	H	Me	Me	2.36	2.38	-	-
19	H	Me	H	Me	H	F	MeO	3.70	3.39	-	-
20	Cl	Me	H	Me	H	F	CF ₃	2.23	2.76	0.79	0.90
21	Me	Me	H	Me	H	Cl	F	3.63	3.67	1.45	1.35
22	H	Me	H	Me	H	MeO	MeO	2.95	3.14	0.51	0.71
23	H	Me	H	H	H	F	F	2.19	2.60	1.41	1.31
24	H	Br	H	H	H	F	F	3.24	2.81	1.51	1.51
25 ^f	H	H	H	Me	H	F	MeO	3.06	3.11	-	-
26 ^f	H	Me	H	H	H	F	MeO	3.54	3.46	0.78	1.70
27	H	Br	H	H	H	F	MeO	2.67	2.42	1.03	0.891
28 ^f	H	H	H	H	Cl	F	F	-	-	1.53	1.36
29 ^f	H	H	H	Me	H	Cl	F	-	-	1.47	1.22
30 ^f	H	H	H	H	Me	F	F	-	-	0.70	1.03
31	H	Me	H	H	H	F	F	2.47	2.14	1.58	1.03
32	H	Me	H	H	H	Cl	Cl	2.42	2.62	1.05	1.35
33	H	Me	H	Me	H	F	F	2.51	2.83	1.45	1.35
34	H	Me	H	H	H	Cl	Cl	2.88	2.68	0.85	1.28
35 ^f	H	Me	H	Me	H	F	F	2.69	1.46	1.43	1.04
36	H	H	H	-	H	F	F	1.02	1.02	-	-
37	H	H	H	-	H	Cl	Cl	-	-	1.63	1.45
38 ^f	H	H	H	-	H	Cl	Cl	-	-	1.63	1.45
39	H	H	H	H	-	Cl	Cl	-	-	2.00	1.93
40	H	H	H	H	-	F	F	-	-	1.47	1.54
41	H	Me	-	H	H	F	F	3.41	3.57	-	-
42	H	Me	-	H	H	Me	Me	2.47	2.29	0.71	0.47
43	H	Me	-	H	H	F	MeO	3.27	3.46	0.50	0.76
44	Cl	Me	-	H	H	F	CF ₃	3.04	2.70	0.72	0.67
45	Me	Me	-	H	H	Cl	F	3.11	3.50	0.81	1.16
46 ^f	H	Me	-	H	H	MeO	MeO	3.04	3.07	0.64	0.34
47	H	Me	-	Me	H	Cl	Cl	4.23	4.07	1.36	1.12
48	H	Me	-	H	H	Cl	Cl	3.55	3.18	1.61	1.49
49	H	Me	-	Me	H	F	F	2.19	2.58	1.35	1.21

^a, compounds shown are additional to those listed in Tables 16 and 17; comp.1-7, 3-phenyls; comp.8-30, 3-(pyridin-2-yl); comp.31-35, 3-(pyridin-2-yl) with methyl at C5 of thiazolidine-4-

one; comp.36-38, 3-(pyridin-3-yl); comp.39 and 40, 3-(pyridin-4-yl); comp. 41-49, 3-(pyrimidin-2-yl)

^b, 50% inhibitory concentration against cytopathic effect of HIV-1 in MT-4 cells

^c, concentration required to reduce 50% viability of MT-4 cells

^d, Eq. 36

^e, Eq. 37

^f, test set compound

Table 19. Physicochemical properties and HIV-1RT inhibitory activity of thiazolidin-4-ones and metathiazanones derivatives (comp. **a** and **b**, Fig. 28) [189]

No	Ar	R	PMIZ	-logEC ₅₀ ^a	
				obsd	cald ^b
1	pyridin-2-yl	Me	2550.89	-	6.09
2	pyridin-3-yl methyl	H	3200.88	4.81	4.92
3	pyridin-3-yl methyl	H	3284.88	5.18	4.77
4	pyridin-3-yl methyl	Me	3307.00	4.56	4.73
5	furan-2-yl methyl	H	2273.00	6.69	6.60
6	furan-2-yl methyl	H	2894.60	5.25	5.47
7	furan-2-yl methyl	Me	2963.52	-	5.35
8	pyridin-2-yl	H	2573.53	-	6.05

^a, 50% inhibitory concentration against cytopathic effect of HIV-1 in MT-4 cells

^b, Eq. 38

Table 20. Physicochemical properties and HIV-1RT inhibitory activity of thiazolidin-4-one derivatives (comp. **c** Fig. 28) [190]

No	R					LogP _(o/w)	MNDO dipole	-logEC ₅₀ ^a	
	2'	3'	4'	5'	6'			obsd	cald ^b
1	Cl	H	H	H	Cl	3.49	3.17	6.69	6.02
2	F	H	H	H	F	2.61	3.76	5.54	5.10
3	Cl	H	H	H	F	3.33	4.46	6.24	6.63
4	H	H	Cl	H	H	2.90	1.78	4.06	4.25
5	Cl	H	H	H	H	2.90	3.38	5.19	5.28
6	H	Cl	H	Cl	H	3.60	0.78	4.07	4.64
7	OMe	H	H	H	H	2.26	3.15	3.94	4.19
8	H	H	OMe	H	H	2.26	3.22	3.77	4.24
9	OMe	H	OMe	OMe	H	2.00	2.42	3.28	3.33
10	H	OMe	OMe	OMe	H	1.75	2.84	3.15	3.24
11	OMe	H	OMe	H	OMe	2.24	0.01	4.86	4.85
12	Me	H	H	H	H	2.60	2.21	4.54	4.09
13	Me	H	H	H	Me	2.90	2.21	5.11	4.53
14	F	F	F	F	F	3.06	1.04	4.33	4.01
15	1-Naphthyl					3.53	2.47	5.26	5.62

^a, 50% inhibitory concentration against cytopathic effect of HIV-1 in MT-4 cells

^b, Eq.39

Table 21: Physicochemical properties and antifungal activity of 2,3,4-substituted thiazolidines
(Fig.29) [191]

No.	R ^a	R ₁ ^b	TREF	FR _p	σR _p	VwR ₁	MRR ₂	-logMIC ^c							
								CN		TM		AF		CA	
								obsd	obsd	cald ^d	obsd	cald ^e	obsd	cald ^f	
1	H	H	55.6	0.00	0.00	0.02	0.00	0.62	0.62	0.74	I	I	I ^g		
2	Cl	H	60.4	0.41	0.23	0.02	0.00	I	0.69	0.75	I	I	I		
3	F	H	55.8	0.43	0.06	0.02	0.00	0.74	0.74	0.72	I	I	I		
4	OH	H	57.3	0.29	-0.37	0.02	0.00	I	I	I	I	I	I		
5	OMe	H	62.0	0.26	-0.27	0.02	0.00	I	I	I	I	I	I		
6	\$	H	68.5	0.00	0.00	0.02	0.00	I	I	I	I	I	I		
7	£	H	75.0	0.26	-0.27	0.02	0.00	I	0.78	0.82	I	I	I		
8	H	¥	80.2	0.00	0.00	0.90	0.00	1.39	0.79	0.72	1.09	1.09	0.49	0.50	
9	Cl	¥	85.0	0.41	0.23	0.90	0.00	1.44	0.84	0.75	0.84	0.82	0.54	0.54	
10	F	¥	80.4	0.43	0.06	0.90	0.00	0.82	0.82	0.72	I	I	0.51	0.52	
11	OH	¥	81.9	0.29	-0.37	0.90	0.00	0.81	0.81	0.73	I	I	0.51	0.52	
12	OMe	¥	86.6	0.26	-0.27	0.90	0.00	1.43	0.53	0.79	0.83	0.83	0.53	0.53	
13	\$	¥	93.1	0.00	0.00	0.90	0.00	0.87	1.17	0.89	I	I	0.57	0.56	
14	£	¥	99.5	0.26	-0.27	0.90	0.00	0.83	0.83	0.82	I	I	0.53	0.53	
15	H	§	84.9	0.00	0.00	0.78	0.00	1.40	0.80	0.58	1.10	1.12	0.50	0.51	
16	Cl	§	89.7	0.41	0.23	0.78	0.00	1.14	0.84	0.89	0.84	0.82	0.54	0.54	
17	F	§	85.1	0.43	0.06	0.78	0.00	0.82	0.82	0.86	I	I	0.52	0.52	
18	OMe	§	91.4	0.26	-0.27	0.78	0.00	1.44	0.54	0.67	0.84	0.87	0.54	0.54	
19	\$	§	97.8	0.00	0.00	0.78	0.00	1.17	0.57	0.70	1.17	1.15	0.57	0.57	
20	£	§	104.3	0.26	-0.27	0.78	0.00	0.91	0.91	0.96	I	I	0.60	0.60	
21	H	¥	97.5	0.00	0.00	0.90	1.03	1.18	0.88	0.92	1.18	1.08	0.58	0.58	
22	H	§	102.3	0.00	0.00	0.78	1.03	1.19	0.58	0.45	0.88	0.92	0.58	0.58	
23	Cl	¥	102.3	0.41	0.23	0.90	1.03	1.52	0.92	0.95	0.92	1.10	0.62	0.61	
24	Cl	§	107.1	0.41	0.23	0.78	1.03	1.22	0.92	1.10	0.92	1.06	0.62	0.62	
25	F	¥	97.7	0.43	0.06	0.90	1.03	I	0.90	0.92	I	I	0.60	0.59	
26	F	§	102.5	0.43	0.06	0.78	1.03	1.51	0.60	0.53	0.90	1.07	0.60	0.60	
27	OMe	¥	104.0	0.26	-0.27	0.90	1.03	1.52	0.91	0.95	0.91	1.10	0.61	0.61	
28	OMe	§	108.7	0.26	-0.27	0.78	1.03	1.52	0.92	0.98	1.22	0.91	0.62	0.61	
29	\$	¥	110.5	0.00	0.00	0.90	1.03	0.94	0.94	0.98	I	I	0.64	0.64	
30	\$	§	115.2	0.00	0.00	0.78	1.03	0.95	1.55	1.16	I	I	0.65	0.64	
31	£	¥	116.9	0.26	-0.27	0.90	1.03	0.97	1.27	1.00	I	I	0.67	0.67	
32	£	§	121.7	0.26	-0.27	0.78	1.03	0.98	0.98	1.18	I	I	0.68	0.67	
33	H	¥	122.2	0.00	0.00	0.90	25.36	1.56	0.96	1.04	0.96	1.09	0.66	0.66	
34	H	§	126.9	0.00	0.00	0.78	25.36	1.26	0.96	1.07	0.96	1.09	0.66	0.66	
35	Cl	¥	127.0	0.41	0.23	0.90	25.36	0.99	0.99	1.07	0.99	1.09	I	I	
36	Cl	§	131.7	0.41	0.23	0.78	25.36	0.99	1.00	1.09	1.00	1.09	0.69	0.69	
37	F	¥	122.4	0.43	0.06	0.90	25.36	1.28	0.98	1.03	1.28	1.07	0.68	0.67	
38	F	§	127.1	0.43	0.06	0.78	25.36	1.88	0.98	1.05	1.28	1.07	0.68	0.68	
39	Me	¥	128.6	0.26	-0.27	0.90	25.36	1.89	0.99	0.96	1.29	1.07	0.69	0.69	
40	OMe	§	133.4	0.26	-0.27	0.78	25.36	1.29	1.29	1.08	1.29	1.07	0.69	0.69	
41	\$	¥	135.1	0.00	0.00	0.90	25.36	1.31	1.01	1.11	1.01	1.09	0.71	0.72	
42	\$	§	139.8	0.00	0.00	0.78	25.36	1.62	1.02	1.09	1.02	0.98	0.72	0.72	
43	£	¥	141.5	0.26	-0.27	0.90	25.36	1.34	1.04	1.02	1.04	1.09	0.74	0.75	
44	£	§	146.3	0.26	-0.27	0.78	25.36	1.34	1.04	1.17	1.04	1.09	0.74	0.76	
45	H	¥	111.2	0.00	0.00	0.90	14.96	1.53	0.93	0.99	0.93	0.93	0.62	0.62	
46	H	§	116.0	0.00	0.00	0.78	14.96	0.93	0.63	0.77	0.93	0.91	0.63	0.62	
47	Cl	¥	116.0	0.41	0.23	0.90	14.96	1.86	0.66	0.93	1.26	1.08	0.66	0.66	
48	Cl	§	120.8	0.41	0.23	0.78	14.96	0.96	0.95	0.74	0.66	0.65	0.66	0.66	
49	F	¥	111.4	0.43	0.06	0.90	14.96	1.55	0.94	0.88	0.94	1.09	0.64	0.64	
50	F	§	116.2	0.43	0.06	0.78	14.96	1.25	0.65	0.77	0.65	0.65	0.65	0.64	
51	OMe	¥	117.7	0.26	-0.27	0.90	14.96	0.96	0.96	1.02	0.66	0.68	0.66	0.65	
52	OMe	§	122.4	0.26	-0.27	0.78	14.96	0.96	0.98	0.88	0.66	0.65	0.66	0.66	
53	\$	¥	124.1	0.00	0.00	0.90	14.96	0.98	0.98	1.05	I	I	0.68	0.68	

54	\$	§	128.9	0.00	0.00	0.78	14.96	0.99	0.99	1.09	I	0.69	0.69	
55	£	¥	130.6	0.26	-0.27	0.90	14.96	1.31	0.71	0.87	1.31	1.89	0.71	0.71
56	£	§	135.3	0.26	-0.27	0.78	14.96	1.31	1.01	0.79	1.31	1.32	0.71	0.72

^a, \$, £ correspond to 2,5-dimethoxy and 3,4,5-trimethoxy, respectively.

^b, ¥, § correspond to CO₂-*t*-Bu and CPh, respectively.

^c, minimum inhibitory concentration in NCCLS protocol

^d, Eq.41

^e, Eq.42

^f, Eq.46

^g, inactive under test conditions

Table 22. Physicochemical properties and fungicidal activity of pyridazinonethiadiazoles (Fig. 32) [193]

	R ₁	R ₂	$\Sigma\sigma$	ΣF	$\Sigma\pi$	ΣEs	D ^a	
							obsd	calcd ^b
1	2-Cl	3-CF ₃	0.66	0.79	1.59	-1.21	-2.30	-2.49
2	2-Cl	2-F	0.29	0.07	0.85	-1.43	-3.57	-2.90
3	2-Cl	H	0.23	0.41	0.71	-0.97	-3.16	-2.96
4	H	2-F	0.06	-0.34	0.14	-0.46	-2.58	-2.79
5	H	3-CF ₃	0.43	0.38	0.88	-0.24	-2.46	-2.38
6	2,6-Cl ₂	3-CF ₃	0.89	1.19	2.30	-2.18	-2.70	-2.60
7	2,6-Cl ₂	2-F	0.52	0.47	1.56	-2.40	-3.01	-3.00
8	4-Cl	3-CF ₃	0.66	0.79	1.59	-1.21	-2.44	-2.49
9	4-Cl	2-F	0.29	0.07	0.85	-1.43	-2.67	-2.90
10	2,4,5-Cl ₃	2-F	0.75	0.41	2.27	-3.37	-2.50	-2.68
11	2,4,5-Cl ₃	3-CF ₃	1.12	0.89	3.01	-3.15	-2.36	-2.04
12	2,4-di-Me	3-CF ₃	0.09	1.61	2.00	-2.72	-1.69	-1.75
13	2,4-di-Me	2-F	-0.28	0.30	1.26	-2.94	-1.66	-1.60
14	2,4-Cl ₂	2-F	0.52	-0.42	1.56	-2.40	-2.05	-2.17
15	2,4-Cl ₂	3-CF ₃	0.89	0.48	2.30	-2.18	-1.74	-1.93
16	2,4-Cl ₂	H	0.46	1.20	1.42	-1.94	-3.23	-3.42

^a, $D = \log[a/(100-a)] - \log Mw$; where, **a** is the percentage inhibition and Mw is the molecular weight of test compound

^b, Eq. 48

Table 23. Physicochemical properties and octopamine agonist activity of 2-(arylimino)thiazolidines (Fig. 34) [203]

No.	X	$\Sigma \pi$	σ_p	E_s^m	$\log V_{\max}^a$	
					obsd	calcd ^b
1	H	0.00	0.00	0.00	0.92	0.78
2	3-Cl	0.87	0.00	-0.97	0.54	0.75
3	3-NO ₂	0.23	0.00	-2.52	0.28	0.17
4	4-F	0.12	0.06	0.00	0.75	0.83
5	4-Me	0.50	-0.17	0.00	0.88	0.89
6	4-CN	-0.21	0.66	0.00	0.92	0.84
7	4-EtO	0.48	-0.24	0.00	0.69	0.87
8	2,4-Cl ₂	1.34	0.23	0.00	1.25	1.17
9	2,4-F ₂	0.22	0.06	0.00	0.60	0.85
10	2-Br,4-Me	1.12	-0.17	0.00	0.89	1.05
11	2-NO ₂ , 4-Me	0.36	-0.17	0.00	0.56	0.85
12	2-NO ₂ , 4-OMe	0.10	-0.27	0.00	0.65	0.71
13	2-Me,4-Br	1.32	0.32	0.00	1.61	1.18
14	2-Me,4-Cl	1.16	0.23	0.00	1.49	1.13
15	2-Me,4-F	-0.11	0.06	0.00	1.15	0.77
16	2-Me,4-I	0.01	0.18	0.00	1.38	0.82
17	2-Me,4-NO ₂	0.61	0.78	0.00	1.21	1.08
18	2,4-Me ₂	0.81	-0.17	0.00	1.02	0.97
19	2,4-(MeO) ₂	-0.31	-0.27	0.00	0.53	0.66
20	2-Et, 4-Br	1.78	0.23	0.00	1.49	1.29
21	2,5-Cl ₂	1.36	0.00	-0.97	0.89	0.88
22	2-Cl,5-CF ₃	1.70	0.00	-2.40	0.66	0.59
23	2,5-F ₂	0.43	0.00	-0.46	1.08	0.77
24	2-Me,5-Cl	1.18	0.00	-0.97	1.03	0.83
25	2-MeO,5-Cl	0.52	0.00	-0.97	0.49	0.66
26	2,5-(MeO) ₂	-0.21	0.00	-0.55	0.34	0.58
27	2-Cl,6-Me	0.80	0.00	0.00	0.95	0.99
28	2,6-F ₂	0.20	0.00	0.00	0.56	0.84
29	2,6- <i>i</i> Pr ₂	2.30	0.00	0.00	1.38	1.39
30	3-Cl,4-Me	1.37	-0.17	-0.97	0.53	0.85
31	3-NO ₂ ,4-Cl	1.08	0.23	-2.52	0.56	0.44
32	3-CF ₃ ,4-Cl	2.06	0.23	-2.40	0.86	0.72
33	3,4-(MeO) ₂	0.18	-0.27	-0.55	0.49	0.64
34	3,5-Cl ₂	1.74	0.00	-0.97	0.89	0.98
35	3,5-(Me) ₂	1.08	0.00	-1.24	0.57	0.74
36	3,5-(CF ₃) ₂	2.42	0.00	-2.40	0.94	0.78
37	3,5-(MeO) ₂	0.28	0.00	-0.55	0.60	0.71
38	2,3,4-Cl ₃	2.21	0.23	-0.97	0.93	1.14
39	2,4,5-Cl ₃	2.21	2.23	-0.97	1.13	1.49
40	2,3,5,6-F ₄	0.86	0.00	-0.46	1.06	0.89
41	2,3,4,5,6-F ₅	0.98	0.06	-0.46	0.73	0.93

^a, V_{\max} is the maximal efficacy of the compound against adenylate cyclase in thoracic nerve cord of *Periplaneta americana* L. relative to 1 mM of octopamine

^b, Eq. 49

Table 24. Physicochemical properties and octopamine agonist activity of 2-(substituted benzylamino)-2-thiazolines series (Fig. 35) [206]

No	R	σ_m	Es ^m	logV _{max} ^a	
				obsd	cald ^b
1	H	0.00	0.00	1.32	1.41
2	2-Br	0.00	0.00	1.44	1.41
3	2-Cl	0.00	0.00	1.39	1.41
4	2-F	0.00	0.00	1.46	1.41
5	2-Me	0.00	0.00	1.48	1.41
6	2-CF ₃	0.00	0.00	1.36	1.41
7	3-F	0.34	-0.46	1.61	1.58
8	3-CF ₃	0.43	-2.40	1.42	1.42
9	4-Cl	0.00	0.00	1.35	1.41
10	4-Me	0.00	0.00	1.41	1.41
11	4-OMe	0.00	0.00	1.45	1.41
12	2,3-Cl ₂	0.23	-0.97	1.46	1.45
13	2,4-F ₂	0.00	0.00	1.38	1.41
14	2-F,4-Cl	0.00	0.00	1.46	1.41
15	2,5-Cl ₂	0.23	-0.97	1.45	1.45
16	2,5-F ₂	0.06	-0.46	1.43	1.40
17	3,5-Cl ₂	0.74	-1.94	1.66	1.68

^a, V_{max} is the maximal efficacy of the compound against adenylate cyclase in thoracic nerve cord of *Periplaneta americana* L. relative to 1 mM of octopamine

^b, Eq.50

Table 25. Physicochemical properties and octopamine agonist activity of thiazolidine derivatives (Fig. 36) [215, 216]

No	LowEne	SXZF	JX	R	pK _i ^a				
					obsd	cald ^b	cald ^c	cald ^d	cald ^e
1	8.85	0.69	2.18	55.60	8.21	8.20	7.95	8.02	8.32
2	63.71	0.87	2.30	60.40	5.21	5.23	5.36	5.15	5.45
3	49.98	0.78	1.86	50.80	4.00	3.99	3.95	3.82	3.96
4	-5.69	0.88	1.89	60.20	7.16	7.19	7.16	7.22	7.17
5	52.65	0.71	2.25	57.30	8.05	8.00	8.01	8.01	7.78
6	37.67	0.80	2.29	57.80	8.41	8.43	8.84	8.46	8.29
7	73.53	0.69	1.92	66.60	4.11	4.11	4.31	4.22	3.95
8	88.28	0.67	2.33	71.50	7.21	7.25	6.89	7.22	7.11
9	106.18	0.78	2.41	74.00	5.27	5.24	5.22	5.42	5.34
10	13.91	0.86	2.00	49.10	7.11	7.11	7.06	7.19	7.38

^a, K_i is the concentration of octopamine agonist necessary for half-maximal inhibition of Pheromone biosynthesis activating neuropeptide (PBAN) binding at 1 pmol/intersegment

^b, Eq.51, ref 215

^c, Eq.52, ref 216

^d, Eq.53, ref 216

^e, Eq.54, ref 216

Table 26. Physicochemical properties and trehalase inhibitory activities of 2-aryliminothiazolidine/oxazolidine derivatives (comp. **b**, Fig 37) [219]

No	R	X	$d_2(\text{\AA})^2$	V_1/V_2	D	pIC_{50}^a	
						obsd	cald ^b
1	2-F	O	4.55	3.21	0.19	4.21	4.05
2	2-F	S	4.55	3.62	0.16	3.08	2.97
3	4-F	O	4.55	2.97	0.15	3.58	3.62
4	4-F	S	4.55	3.28	0.18	3.24	2.77
5	2,4-F ₂	O	4.55	3.14	0.16	3.05	3.53
6	2,4-F ₂	S	4.55	3.55	0.16	2.21	2.48
7	3-Cl, 4-F	O	5.09	3.35	0.14	4.45	4.50
8	3-Cl, 4-F	S	5.10	3.70	0.14	3.62	3.60
9	2,3,4-F ₃	O	4.77	3.38	0.16	4.07	3.81
10	2,3,4-F ₃	S	4.77	3.63	0.15	3.15	3.34

^a percent inhibition = $[1-A/B] \times 100$, where A and B are the molarity of glucose solution with and without test compound

^b, Eq.55